Vaccines and Global Health: The Week in Review
26 June 2021 :: Issue 613
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]
A. Milestones :: Perspectives :: Featured Journal Content
B. Emergencies
C. WHO; CDC [U.S., Africa, China]
D. Announcements
E. Journal Watch
F. Media Watch
Editor’s Note:
As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:
david.r.curry@ge2p2global.org

Editor’s Note:
These Gavi announcements represent critical milestones in COVID response and, as such, we present their full text.

Gavi Board strengthens commitment to reaching the most vulnerable through routine immunisation and COVAX
:: Gavi Board makes key strategic decisions to support Gavi’s 5.0 strategy of leaving no child behind through immunisation; doubles down on ambitious targets for COVAX
:: New market-shaping strategy, alliances with civil society among measures aimed at reducing the number of children receiving no doses of vaccine, by 25% globally - by 2025
:: US$ 775 million in COVAX delivery funding approved for lower-income economies that are eligible for support through the Gavi COVAX Advance Market Commitment (AMC)
:: José Manuel Barroso: “Protecting the most vulnerable and enabling access to the lifesaving power of vaccines has always been at the heart of Gavi’s mission. As Africa, with the lowest vaccine coverage in the world, and other regions face a renewed surge of the virus, the global community must step up now to help COVAX to meet its ambitious equitable access goals to support these countries.”

Geneva, 25 June 2021 – The Board of Gavi, the Vaccine Alliance has made several decisions to strengthen the organisation’s commitment to protecting the most vulnerable everywhere – through routine immunisation, access to COVID-19 vaccines via the Gavi-hosted COVAX Facility and support for outbreak preparedness and response activities.

In addition to taking decisions relating to Gavi’s strategic direction, the Board united in condemning today’s gross inequity in vaccine delivery and committed itself to redoubling efforts to close the gap.

“Protecting the most vulnerable and enabling equitable access to lifesaving vaccines has always been at the heart of Gavi’s mission,” said José Manuel Barroso, Chair of the Gavi Board. “As Africa, with the lowest vaccine coverage in the world, and other regions face a renewed surge of the virus, we must use all our resourcefulness and innovation to help those most at risk: the global community must step up now to help COVAX to meet its ambitious equitable goals to support these countries.”

Supporting COVAX to deliver
Earlier this week COVAX, the world’s first global procurement facility for pandemic vaccines, released an updated supply forecast demonstrating that, thanks to new agreements with manufacturers and dose-sharing by higher income economies, supplies were expected to reach two billion doses in January 2022 – only a short time later than previous forecasts, despite severe on-going supply delays. According to the forecast, COVAX’s goal of delivering 1.8 billion doses to lower-income economies eligible for donor-supported doses via the Gavi COVAX Advance Market Commitment (COVAX AMC) would be reached in the first quarter of 2022.

In order to help prepare countries for this rapid scale up, the Gavi Board approved new funding of US$ 775 million to support the delivery of COVAX-funded doses in lower-income economies and humanitarian zones over the next two years. Gavi is co-lead of COVAX and hosts the Office of the COVAX Facility. The funding comes in addition to a previously Board-approved envelope of US$ 150 million in delivery support.

The Board also approved an evolution in the model of participation for self-financing participants (SFPs) of the COVAX Facility. Starting in 2022, the model will enable SFPs that rely on the Facility to access doses to continue procuring vaccines through COVAX under revised terms and conditions. The move, based on lessons learned over the past year, will enable simplified operations and reduce financial risks to Gavi and COVAX.

“As the only global solution designed around equitable access to COVID-19 vaccines, we need to continue to adapt the COVAX model as the pandemic evolves,” said Dr Seth Berkley, CEO of Gavi. “The additional delivery support funding will help make sure that COVAX-funded doses are rapidly and efficiently rolled out in lower-income economies. But it will not help us end the acute phase of pandemic alone: to do this, we need governments, manufacturers and multilateral development banks to truly get behind COVAX and get us doses now so we can scale up protecting lives and do so quickly.”

**Reaching the most vulnerable with routine immunisation**
Many decisions at the two-day board meeting concerned Gavi’s new 5.0 strategy.

Guiding the Alliance’s mission over the period 2021–2025, Gavi 5.0’s goal is to “leave no one behind with immunisation”, with a core focus on reaching “zero-dose” children and missed communities, with equity as the organising principle.

The following decisions are aimed at providing a critical framework for achieving this goal – building on Gavi’s existing strengths, as well as forming new partnerships and evolving key policies:

:: **A measurement framework** for the work of the Alliance in the next five years. In line with its 5.0 overarching objective of leaving no one behind, Gavi will aim to reduce the number of zero-dose children globally by 25% in 2021–2025. Other indicators include immunising an additional 300 million children and preventing 7-8 million future deaths through Gavi’s support for routine immunisation programmes and vaccination campaigns, while unlocking US$ 80-100 billion in economic benefits.

:: **A 2021-2025 Market Shaping Strategy** that will foster a sustainable, competitive future supplier base by encouraging healthy demand through a more coordinated and country-centric approach. The strategy will also focus on enabling vaccine product innovations that best meet country needs and that
directly contribute to the Gavi 5.0 goals of increasing equitable vaccine coverage and reaching zero-dose children and missed communities.

:: **The Civil Society and Community Engagement Approach** to ensure effective management, enhanced capacity and efficient funding of Gavi’s engagement with civil society organisations (CSOs). Beyond their comparative advantage in reaching zero-dose children and missed communities, CSOs have key roles to play in helping to ensure immunisation is maintained, restored and strengthened in the context of COVID-19, and that vaccines are introduced in an equitable way.

:: An initial investment of up to US$ 5 million for the **Vaccine Innovation Prioritisation Strategy (VIPS)** for costs related to short-term (2021–2023) activities to provide guidance for and incentivise development of three innovation priorities, including clarifying the potential demand, defining investment cases and understanding the need for and design of push and pull funding mechanisms, as well as generating evidence of programmatic impact.

:: **Yellow Fever diagnostic capacity strengthening** initially to create the first commercial test kits for Yellow Fever, which has been accomplished, and support for costs related to the procurement and distribution of laboratory reagents, supplies and equipment which has been extended until the end of 2022. The costs remain within the initially approved envelope of US$ 8.2 million authorised for the 2019–2021 period.

:: An approach to strengthen **fiduciary risk assurance and** financial management of Gavi grants in the 5.0 strategic period, with associated investment of US$ 139 million for 2022–2025. As Gavi funding will increasingly be channelled through government systems, the investments will be used to help build sustainable financial management capacity of government systems, as well as ensure the continued use of fiduciary risk mitigation mechanisms.

Encompassing both COVAX and Gavi 5.0 is **Gavi’s risk appetite statement, which defines the criteria and trade-off considerations that guide the Alliance’s appetite for risk at the mission, strategy and organisational level**. Against the backdrop of the ongoing COVID-19 pandemic, the Board approved an approach where the Alliance will seek to find the right balance between successfully delivering on the COVAX mission, where Gavi plays a central role, while minimising risks to Gavi’s core resources and programmes, acknowledging the reality that a higher risk appetite is needed in a pandemic setting.

**Key departures and appointments**
The Board approved a one-year exceptional contract extension for Gavi CEO Dr Seth Berkley to guarantee stable and strong leadership of the Alliance in this critical time and ensure successful implementation of COVAX and Gavi 5.0. The current CEO’s 3rd term will now end in August 2023 and succession planning will be led by Gavi Board Chair.

The Board also welcomed new Board members including Awa Marie Coll Seck, Naguib Kheraj and Bounfeng Phoummalaysith.

In addition, the Board thanked Stephen Zinser and Muhammad Ali Pate as their terms as Board members concluded. Stephen Zinser has been a Gavi Board member since 2014 and has guided Gavi’s transition through two strategic periods. Muhammad Ali Pate began his term as a Board member in
July 2019 lending his counsel and extensive experience to support the work of the Alliance. Mr Pate has also been an invaluable member of Market Sensitive Decisions Committee (MSDC) since October 2019.

Finally, the Gavi Board gave a warm send-off to Bill Roedy. Mr Roedy joined Gavi in 2010 as its first envoy. He was appointed to the Board in 2015 and has been Board Vice Chair in 2018–2019. Mr Roedy is recognised as a global health leader who has used his extensive network and experience to champion both Gavi and immunisation.

What does COVAX’s latest supply forecast tell us?
23 June 2021 – by Aurélia Nguyen, Managing Director, Office of the COVAX Facility

COVAX’s latest supply forecast is now published. According to this latest assessment, the vaccines pillar of the ACT-Accelerator will have 1.9 billion doses available for supply by the end of 2021 and, thanks to a number of recently signed advance purchase agreements, now has signed deals in place for a total of 2.8 billion doses in 2021 and 2022, with a further 1.3 billion secured should it need them. This is due in large part to the pledges made by donors to the Gavi COVAX AMC.

The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, as well as the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale. But what does it mean in the context of COVAX’s stated goal of ending the acute phase of the pandemic? Unsurprisingly, given that it represents the most ambitious roll-out of vaccines in history, the numbers in the document provide some important insights.

Short term supply concerns persist
The first observation is that, despite remaining more or less on target for its original year-end goal to make 2 billion doses available to participants, COVAX deliveries will continue to be very lean through July and August. This is a result of a number of well-documented factors, including the diversion of production at the Serum Institute of India (SII), an important early supplier, to meet acute domestic needs, as well as challenges scaling up deliveries across AstraZeneca’s global manufacturing network and fulfilling requirements to enable delivery of the Pfizer vaccine - COVAX’s other two currently active suppliers.

Dose sharing is becoming an important immediate-term source of doses
In response to COVAX’s call to countries with excess supply to help alleviate short term supply shortages by sharing doses, a number of donors have now stepped forward. According to the forecast, 515 million doses have been pledged, and they should start becoming available in significant numbers very soon, with 80 million expected by the end of July and a total of 115 million by the end of August. Apart from the period between September and October when 100 million dose donations are expected to come online, supply from countries’ pledges are anticipated to be relatively evenly paced through the year, with around 40-50 million donated doses available each month until the end of December.

Absorptive capacity is a very real concern
The reason why COVAX has been urging donors to share doses in the third quarter rather than later in the year is to avoid the possibility of COVAX participants’ health systems becoming too stretched by the volume of deliveries later in the year. COVAX’s partners work closely with countries in the Facility,
especially the 92 lower-income economies eligible for support through the Gavi COVAX AMC, to ensure conditions are in place to enable mass vaccination. From September onwards, the forecast projects that a number in the region of 400 million doses will become available every month so it’s critical that sufficient funding is unlocked, where necessary, to help countries prepare for this.

**COVAX will keep on doing deals**
COVAX has currently signed deals for 2.8 billion doses. This is more than enough to fulfil our goal of delivering 1.8 billion doses to AMC economies as well as supplying the approximately 480 million doses ordered by self-financing economies. A key reason COVAX has signed deals and options for more doses is to allow participants that want to receive more doses to procure them through cost-sharing; taking advantage of COVAX’s pricing and access, plus other advantages such as its no-fault compensation scheme, to raise protection rates in their countries further. COVAX’s goal from the beginning has also been to build a portfolio of 10-12 vaccines to ensure suitability for all contexts and to mitigate risks around over-reliance on specific sources in case there are issues related to failure at the R&D stage, regulatory hurdles or supply challenges. Gavi, on behalf of the Facility, also negotiates key flexibilities such as options and potential access to future variant-adapted vaccines to ensure the Facility portfolio can continue to be tailored to participants’ evolving needs. To this end, expect further advance purchase agreements to be announced in the coming weeks and months.

**Mind the gap (between availability and deliveries)**
One important distinction between the supply forecast and COVAX’s delivery tracker, which is hosted by COVAX’s key delivery partner UNICEF, is that the forecast tracks the availability of doses at the manufacturer. With a number of technical, regulatory and legal tasks to be overcome before doses can be released, there is always a delay between doses becoming available and being shipped and delivered to countries. Although COVAX partners work closely with countries, manufacturers and other stakeholders to minimise this gap, the estimated timings shown here reflect the availability of doses at the manufacturer and not in country.

**The Supply Forecast will continue to evolve**
There are a number of other caveats worth noting in the forecast too, all of which relate to the scale and number of moving pieces across COVAX’s unprecedented end-to-end solution. The timing of regulatory approval, for example, can be volatile, especially since it is common that more than one manufacturing site is involved in the supply chain. Likewise local licensing or export controls can and have had an impact on supply schedules. For these reasons as well as the fact that more secured doses are expected to be added to its portfolio, COVAX will aim to keep this forecast updated as regularly as possible through 2021 and beyond. Watch this space

UNHCR calls on states to remove barriers to access to COVID-19 vaccines for refugees
24 June 2021

Four months since the first delivery of COVID-19 vaccines from the COVAX facility, the global initiative to ensure the vaccines’ equitable distribution, UNHCR, the UN Refugee Agency, calls on States to expedite the roll-out of vaccination campaigns and remove barriers that limit access to vaccines for the world’s 82.4 million forcibly displaced people.
UNHCR is monitoring the inclusion of refugees and asylum seekers in COVID-19 vaccination plans and roll-out in 162 countries.

Of the 126 countries with a refugee population of more than 500 people, UNHCR has confirmed that 123 have either explicitly included refugees in their vaccination plans or provided assurances that they will do so. This is also the case for asylum-seekers in 93 out of 96 countries.

Moreover, UNHCR is able to confirm that refugees and asylum-seekers have begun receiving COVID-19 vaccinations in 91 of the 162 countries monitored. UNHCR commends the States that have included these forcibly displaced populations in the vaccine roll-out and urges others to follow their lead. “Around the world, we have seen an unwavering commitment to not leave refugees behind in COVID-19 vaccination planning,” said Ann Burton, Chief of UNHCR’s Public Health Section. “But barriers to vaccination persist. Stronger efforts are needed to ensure that States’ assurances for refugee inclusion turn into tangible reality.”

To register for or receive vaccinations, some States require identity documents which refugees often do not have. Others have set up online systems that can deter or prevent people without access to the Internet or who are not computer literate from registering for vaccines.

In several countries, vaccination sites are located far from where refugees live, which could deter them from seeking immunization. This is the case particularly in Sub-Saharan Africa, where newly reported COVID-19 cases are on the rise, in contrast to the observable decline in many parts of the world. Other factors that prevent people from getting vaccinated include the real or perceived cost of the vaccine services, language barriers, as well as lack of information, misinformation and limited opportunities to ask questions, which can lead to vaccine hesitancy.

UNHCR welcomes the efforts of States to overcome these hurdles. Moldova and Serbia prioritized bringing the vaccine to people living in asylum centers, while in Serbia vaccination is completed for refugees living in private accommodation as well. Senegal and Cameroon allowed refugees to register in designated health facilities and city councils in the vicinity of their communities. Portugal introduced a specific registration system for undocumented persons to ensure that no one is excluded from the vaccine roll-out. Meanwhile, in the Democratic Republic of the Congo (DRC) the region’s largest awareness-raising campaign on COVID-19 has reached more than 1.7 million people since the beginning of the pandemic.

UNHCR stands ready to work with all States to ensure at least 20 per cent of refugees are vaccinated by the end of 2021, as per the target set by COVAX. The Agency also urges States with surplus vaccine doses to share them with lower and middle-income countries and to support the COVAX facility. “Beyond the moral imperative, this is in our collective self-interest,” said Burton. “As long as the pandemic remains out of control somewhere, it is threat for everyone everywhere.”

::: WHO supporting South African consortium to establish first COVID mRNA vaccine technology transfer hub
Geneva/Johannesburg/Paris: The World Health Organization (WHO) and its COVAX partners are working with a South African consortium comprising Biovac, Afrigen Biologics and Vaccines, a network
of universities and the Africa Centres for Disease Control and Prevention (CDC) to establish its first COVID mRNA vaccine technology transfer hub.

The move follows WHO’s global call for Expression of Interest (EOI) on 16 April 2021 to establish COVID mRNA vaccine technology transfer hubs to scale up production and access to COVID vaccines. Over the coming weeks, the partners will negotiate details with the Government of South Africa and public and private partners inside the country and from around the world.

South African President Cyril Ramaphosa said: “The COVID-19 pandemic has revealed the full extent of the vaccine gap between developed and developing economies, and how that gap can severely undermine global health security. This landmark initiative is a major advance in the international effort to build vaccine development and manufacturing capacity that will put Africa on a path to self-determination. South Africa welcomes the opportunity to host a vaccine technology transfer hub and to build on the capacity and expertise that already exists on the continent to contribute to this effort.”

“This is great news, particularly for Africa, which has the least access to vaccines,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “COVID-19 has highlighted the importance of local production to address health emergencies, strengthen regional health security and expand sustainable access to health products.”

...Technology transfer hubs are training facilities where the technology is established at industrial scale and clinical development performed. Interested manufacturers from low- and middle-income countries can receive training and any necessary licenses to the technology. WHO and partners will bring in the production know-how, quality control and necessary licenses to a single entity to facilitate a broad and rapid technology transfer to multiple recipients.

The technology transfer hub will benefit from the Medicines Patent Pool’s (MPP’s) vast experience of intellectual property (IP) management and issuing of IP licenses. MPP is also assisting WHO to negotiate with technical partners and supporting in the governance of the hubs...

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Jun 25, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures:  179M total confirmed cases; 3.9M total confirmed deaths
Global vaccines administered: 2.79B
Number of Countries: 26 [26]
COVAX First Allocations (Number of Doses): 73M [73M]
COVAX Delivered (Number of Doses): 15M [15M]
Other Delivered (Number of Doses): 37M [34M]
Total Delivered (Number of Doses): 52M [49M]
Total Administered (Number of Doses): 46M [41M]
Weekly operational update on COVID-19 - 22 June 2021

Overview
In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

:: Shipment of medical kits to support essential health services in Afghanistan
:: Risk Communication and Community Engagement training for frontline responders in Kyrgyzstan
:: Support as COVID-19 cases surge in Africa, nearing first wave peak
:: Release of Basic Psychosocial Skills online course for Pacific COVID-19 responders
:: Infodemic management training in the Democratic Republic of the Congo to support COVID-19 vaccine rollout
:: Launch of an updated COVID-19 National Rapid Response Teams Online Learning Programme and mixed modality trainings in Guinea-Bissau
:: Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
:: Updates on WHO’s financing to support countries in SPRP 2021 implementation and provision of critical supplies.

Weekly epidemiological update on COVID-19 - 22 June 2021

Overview
Global numbers of cases and deaths continued to decrease over the past week (14-20 June 2021) with just over 2.5 million new weekly cases and over 64 000 deaths, a 6% and a 12% decrease respectively, compared to the previous week. While the number of cases reported globally now exceeds 177 million, the lowest weekly case incidence since February 2021 was reported last week. Globally, mortality remains high with more than 9000 deaths reported each day over the past week, however, the number of new deaths reported in the past week decreased across all Regions except for the Eastern Mediterranean and the African Regions.

In this edition, a special focus update is provided on SARS-CoV-2 Variants of Interest (VOIs) and Variants of Concern (VOCs) Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2). This includes updates on emerging evidence surrounding the phenotypic characteristics of VOCs (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance), as well as updates on the geographic distribution of VOCs.

This edition also includes a summary of a Global Consultation on SARS-CoV-2 Variants of Concern and their Impact on Public Health Interventions.
Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 20 June 2021**

Table 2: SARS-CoV-2 Variants of Concern (VOCs) and Variants of Interest (VOIs), as of 22 June 2021

<table>
<thead>
<tr>
<th>WHO label</th>
<th>Pango lineage</th>
<th>GISAID clade</th>
<th>Nextstrain clade</th>
<th>Earliest documented samples</th>
<th>Date of designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha</td>
<td>B.1.1.7</td>
<td>GRY (formerly GR/501Y.V1)</td>
<td>20I (V1)</td>
<td>United Kingdom, Sep-2020</td>
<td>18-Dec-2020</td>
</tr>
<tr>
<td>Beta</td>
<td>B.1.351</td>
<td>GH/501Y.V2</td>
<td>20H (V2)</td>
<td>South Africa, May-2020</td>
<td>18-Dec-2020</td>
</tr>
<tr>
<td>Gamma</td>
<td>P.1</td>
<td>GR/501Y.V3</td>
<td>20J (V3)</td>
<td>Brazil, Nov-2020</td>
<td>11-Jan-2021</td>
</tr>
</tbody>
</table>

Variants of concern (VOCs):

| Zeta      | P.2             | GR/484K.V2 | 20B | Brazil, Apr-2020                   | 17-Mar-2021 |
| Eta       | B.1.525         | G/484K.V3  | 21D | Multiple countries, Dec-2020       | 17-Mar-2021 |
| Theta     | P.3             | GR/1092K.V1| 21E | Philippines, Jan-2021              | 24-Mar-2021 |
| Iota      | B.1.526         | GH/253G.V1 | 21F | United States of America, Nov-2020 | 24-Mar-2021 |
| Kappa     | B.1.617.1       | G/452R.V3  | 21B | India, Oct-2020                    | 4-Apr-2021 |
| Lambda    | C.37            | GR/452Q.V1 | 20D | Peru, Aug-2020                     | 14-Jun-2021 |
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 26 June 2021

For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[No update posted from 16 June 2021 data below; click on the link above for full scale view]

### Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

<table>
<thead>
<tr>
<th>Manufacturer / WHO EUL holder</th>
<th>Name of Vaccine</th>
<th>NRA of Record</th>
<th>Platform</th>
<th>EOI accepted</th>
<th>Pre-submission meeting held</th>
<th>Dossier accepted for review**</th>
<th>Status of assessment**</th>
<th>Decision date***</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. BNT162b2/COMIRNATY</td>
<td>EMA</td>
<td>Nucleoside modified mRNA</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Finalized</td>
<td>31/12/20</td>
</tr>
<tr>
<td>2. AZD1222</td>
<td>EMA</td>
<td>Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Core data finalized</td>
<td>16 April 2021</td>
<td></td>
</tr>
<tr>
<td>3. AstraZeneca</td>
<td>MPOK KOREA</td>
<td>Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Finalized</td>
<td>15 Feb 2021</td>
<td></td>
</tr>
<tr>
<td>4. Gilead Sciences, Inc.</td>
<td>CovSHM1 (ChAdOx1-S-CoV-2)</td>
<td>DCG</td>
<td>Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Finalized</td>
<td>15 Feb 2021</td>
</tr>
<tr>
<td>5. Janssen</td>
<td>Janssen E2</td>
<td>EMA</td>
<td>Recombinant, replication-incompetent adenovirus type-36 (Ad36) vector vaccine encoding the (SARS-CoV-2) S protein</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Core data finalized (US &amp; EU sites)</td>
<td>12 March 2021</td>
</tr>
<tr>
<td>6. Moderna</td>
<td>mRNA-1273</td>
<td>EMA</td>
<td>mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Finalized</td>
<td>30 April 2021</td>
</tr>
<tr>
<td>7. Sanofi Pasteur</td>
<td>SARS-CoV-2 Vaccine (Vero Cell), Inactivated (Vac)</td>
<td>NMFA</td>
<td>Inactivated, produced in Vero cells.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Finalized</td>
<td>07 May 2021</td>
</tr>
</tbody>
</table>

---

### Vaccines

<table>
<thead>
<tr>
<th>Manufacturer / WHO EUL holder</th>
<th>Name of Vaccine</th>
<th>NRA of Record</th>
<th>Platform</th>
<th>EOI accepted</th>
<th>Pre-submission meeting held</th>
<th>Dossier accepted for review**</th>
<th>Status of assessment**</th>
<th>Decision date***</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. Sinovac</td>
<td>SARS-CoV-2 Vaccine (Vero Cell), Inactivated</td>
<td>NMFA</td>
<td>Inactivated, produced in Vero cells.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Finalized</td>
<td>01 June 2021</td>
</tr>
<tr>
<td>10. AstraZeneca</td>
<td>AZD1222</td>
<td>Japan MHFW/MEDA</td>
<td>Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Ongoing</td>
<td>01 June 2021</td>
</tr>
<tr>
<td>11. AstraZeneca</td>
<td>AZD1222</td>
<td>Austria TGA</td>
<td>Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Ongoing</td>
<td>01 June 2021</td>
</tr>
<tr>
<td>12. AstraZeneca</td>
<td>AZ5163</td>
<td>NMFA</td>
<td>Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Rolling data starting June 2021</td>
<td></td>
</tr>
<tr>
<td>13. Novavax</td>
<td>NVX-CoV2373/Covaxin</td>
<td>EMA</td>
<td>Recombinant nanoparticle pre-fusion spike protein formulated with Matrix-M™ adjuvant</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Rolling data starting June 2021</td>
<td></td>
</tr>
<tr>
<td>14. SinoPharm / WBE</td>
<td>Inactivated SARS-CoV-2 Vaccine (Vero Cell)</td>
<td>NMFA</td>
<td>Inactivated, produced in Vero cells.</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>Rolling data starting June 2021</td>
<td></td>
</tr>
</tbody>
</table>
COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

**AstraZeneca**

*Press Releases* - No new digest announcements identified

**BioCubaFarma** – Cuba

*Últimas Noticias*

La apuesta de Cuba por el desarrollo de vacunas propias contra la Covid19 tiene una experiencia de más de 30 años.
24/06/2021 23:27:18
[google translate: Cuba's commitment to the development of its own vaccines against Covid19 has an experience of more than 30 years. 06/24/2021 11:27:18 PM]

**CanSinoBIO**

*News*

CanSinoBIO Announces Approval for Its Group A and Group C Meningococcal Conjugate Vaccine in China
2021-06-23

**Clover Biopharmaceuticals** - China

*News* - No new digest announcements identified

**Curevac** [Bayer Ag – Germany]
**News**  Home  - No new digest announcements identified

**Gamaleya National Center**
*Latest News and Events* - No new digest announcements identified  [See Russia/RFID below]

**IMBCAMS, China**
Home  - No new digest announcements identified

**Janssen/JNJ**
*Press Releases* - No new digest announcements identified

**Moderna**
*Press Releases*
June 22, 2021
**European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022**

**Novavax**
*Press Releases*
**Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre**
Jun 22, 2021
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry announced today that construction of the new Biologics Manufacturing Centre (BMC) at the National Research Council of Canada’s (NRC)’s Royalmount location in Montréal, Québec has been completed.

The partnership will enable the first manufacturing capabilities in Canada for a COVID-19 vaccine once the facility and NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, receive the required Health Canada approvals. Novavax and the NRC are working closely together on technology transfer to establish the step-by-step process of producing NVX-CoV2373 at the BMC...

**Pfizer**
*Recent Press Releases* - No new digest announcements identified

**Sanofi Pasteur**
*Press Releases*
June 22 2021  Press releases
**Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine**

**Serum Institute of India**
*NEWS & ANNOUNCEMENTS* - No corporate announcements identified
[Last media release April 21, 2021]

**Sinopharm/WIBPBIBP**
*News*  - Website not responding at inquiry

**Sinovac**
*Press Releases* - No new digest announcements identified
**Vector State Research Centre of Viralogy and Biotechnology**

*Home - No new digest announcements identified*

**Zhifei Longcom**, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

::::::

**GSK**

*Press releases for media*

**New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline**

23 June 2021

*...Maximising Vaccines and Specialty Medicines*

New GSK will prioritise R&D and commercial investment in Vaccines and Specialty Medicines, which are expected to grow to around three-quarters of company sales by 2026. As part of its 2021-26 outlook, Vaccines is expected to grow sales at a high single-digit % CAGR and Specialty Medicines at a double-digit % CAGR.

The company is focused across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. In addition, New GSK will remain open to opportunities outside these core TAs where there are scale opportunities rooted in immune science and genetic validation.

Capturing the increasing opportunities now seen across the prevention and treatment of disease offers significant scientific and commercial opportunities for New GSK. At the heart of this is the company’s R&D focus on the science of the immune system, human genetics and advanced technologies; and its world-leading capabilities in vaccine and pharmaceutical development.

The company currently has a pipeline of 20 vaccines and 42 medicines – many of which are potential best or first in class opportunities...

**SK Biosciences**

*Press releases*

**SK bioscience to Sign MOU with Andong and North Gyeongsang Province for Expansion of Factories and Sites**

SK invested about 150 billion won in the expansion of existing vaccine manufacturing plants used for mRNA...

2021. 06. 21

::::::

**UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 26 Jun 2021**

An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view since last week’s edition]
17 vaccines approved for use by at least one national regulatory authority

7 vaccines in WHO’s Emergency Use Listing

14.6bn doses secured globally

$2-$40 reported vaccine price range per dose

3.86bn doses secured & optioned through COVAX

89.8M doses shipped through COVAX to 133 countries

<table>
<thead>
<tr>
<th>Deal date</th>
<th>Recipient</th>
<th>Deal type</th>
<th>Vaccine name</th>
<th>Vaccine developer</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>6/8/2021</td>
<td>India</td>
<td>Bilateral</td>
<td>Bharat Biotech</td>
<td>Bharat Biotech</td>
<td></td>
</tr>
<tr>
<td>6/8/2021</td>
<td>India</td>
<td>Bilateral</td>
<td>Serum Institute of India</td>
<td>Serum Institute of India</td>
<td></td>
</tr>
<tr>
<td>6/10/2021</td>
<td>USA for COVAX</td>
<td>Bilateral</td>
<td>Pfizer BioNTech</td>
<td>Pfizer/BioNTech</td>
<td></td>
</tr>
<tr>
<td>6/13/2021</td>
<td>Thailand</td>
<td>Bilateral</td>
<td>Janssen Pharmaceuticals</td>
<td>Janssen</td>
<td></td>
</tr>
<tr>
<td>6/13/2021</td>
<td>Thailand</td>
<td>Bilateral</td>
<td>Pfizer BioNTech</td>
<td>Pfizer/BioNTech</td>
<td></td>
</tr>
<tr>
<td>6/15/2021</td>
<td>Angola</td>
<td>Bilateral</td>
<td>Beijing Institute of Biological Products (CNBG)</td>
<td>Gamaleya Research Institute</td>
<td></td>
</tr>
<tr>
<td>6/15/2021</td>
<td>Djibouti</td>
<td>Bilateral</td>
<td>Sinovac</td>
<td>Sinovac</td>
<td></td>
</tr>
<tr>
<td>6/15/2021</td>
<td>Ghana</td>
<td>Bilateral</td>
<td>Gamaleya Research Institute</td>
<td>Gamaleya Research Institute</td>
<td></td>
</tr>
<tr>
<td>6/15/2021</td>
<td>Guinea</td>
<td>Bilateral</td>
<td>Gamaleya Research Institute</td>
<td>Gamaleya Research Institute</td>
<td></td>
</tr>
</tbody>
</table>

Duke – Launch and Scale Speedometer

**TRACKING COVID-19 VACCINE PURCHASES ACROSS THE GLOBE**
[accessed 26 June 2021]

17.9 billion doses reserved
Countries have purchased vaccine doses from a wide pool of candidates to cover their populations. So far, confirmed purchases cover 11.9 billion doses, with another 6 billion doses currently under negotiation or reserved as optional expansions of existing deals...

High-income countries hedged their bets while low-income countries were left out
In 2020, many high-income countries hedged their bets by purchasing enough doses to vaccinate their populations several times over, even before any candidates were approved and have continued to procure more doses of approved vaccines in 2021, in an effort to receive doses as quickly as possible. Because of global manufacturing constraints, the direct deals made by high-income (and some middle-income) countries mean that a smaller piece of the pie is available for low- and middle-income countries and for equity-focused partnerships like COVAX in 2021...
**Our World in Data**

**Coronavirus (COVID-19) Vaccinations**

Daily COVID-19 vaccine doses administered per 100 people. Jun 25, 2021

Shown is the rolling 7-day average per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).
COVID-19 vaccine doses administered per 100 people, Jun 25, 2021

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

[Bar chart showing vaccination rates per 100 people for various countries, with United Arab Emirates leading at 151.06 doses, followed by Israel at 123.33, Bahrain at 118.11, United Kingdom at 111.9 (Jun 24, 2021), United States at 96.04, Germany at 85.26, Italy at 80.93, China at 79.47, France at 75.47 (Jun 24, 2021), Brazil at 43.71 (Jun 24, 2021), and the World at 36.98.]

Share of the population fully vaccinated against COVID-19, Jun 25, 2021

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

[Bar chart showing the share of the population fully vaccinated for various countries, with Israel leading at 59.6%, followed by Bahrain at 56.4%, Mongolia at 52.6%, United Kingdom at 47.3% (Jun 24, 2021), United States at 45.3%, Germany at 34.5%, Italy at 28.6%, France at 27.5% (Jun 24, 2021), Mexico at 14.2% (Jun 24, 2021), Brazil at 11.6% (Jun 24, 2021), World at 10.4%, and India at 3.9%.]
U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Vaccines and Related Biological Products Advisory Committee
:: No meetings scheduled

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Remarks by President Biden Highlighting the Importance of Getting Vaccinated and Kicking Off a Community Canvassing Event
June 24, 2021 • Speeches and Remarks

Press Briefing by White House COVID-19 Response Team and Public Health Officials
June 22, 2021 • Press Briefings

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases
News: Additional manufacturing site for COVID-19 Vaccine Janssen (new)
CHMP, Last updated: 25/06/2021
  ... The site, located in Anagni, Italy, is operated by Catalent Anagni SRL. The site will perform finished product manufacturing.
  The site is expected to support the continued supply of COVID-19 Vaccine Janssen in the European Union.
  This recommendation does not require a European Commission decision and the site can become operational immediately.

News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021 (new)
CHMP, Last updated: 25/06/2021

News: Two additional manufacturing sites for BioNTech/Pfizer’s COVID-19 vaccine (new)
CHMP, Last updated: 22/06/2021
  ... One site, located in Reinbek, Germany, is operated by Allergopharma GmbH & Co. KG. The other in Stein, Switzerland, is operated by Novartis Pharma. The sites will perform finished product manufacturing steps at different stages of the process.
  The two new sites are expected to support the continued supply of Comirnaty in the European Union. This recommendation does not require a European Commission decision and the sites can become operational immediately.
European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en

Latest Updates
News
ECDC statement on the SARS-CoV-2 Delta variant in the EU/EEA
23 Jun 2021
ECDC publishes a threat assessment brief on the implications of the spread of the Delta variant of concern for the EU/EEA.
Dr. Andrea Ammon, ECDC Director:
Variants of SARS-CoV-2 are emerging at a significant rate worldwide. ECDC is constantly analysing the characteristics of these variants to rapidly inform public health authorities in the European Union. Some variants can put our efforts to control the pandemic at risk and require immediate actions.

Based on available scientific evidence, the Delta variant is more transmissible than other circulating variants and we estimate that by the end of August it will represent 90% of all SARS-CoV-2 viruses circulating in the European Union.

Unfortunately, preliminary data shows that it can also infect individuals that have received only one dose of the currently available vaccines. It is very likely that the Delta variant will circulate extensively during the summer, particularly among younger individuals that are not targeted for vaccination. This could cause a risk for the more vulnerable individuals to be infected and experience severe illness and death if they are not fully vaccinated.

The good news is that having received two doses of any of the currently available vaccines provides high protection against this variant and its consequences. However, about 30% of individuals older than 80 years and about 40% of individuals older than 60 years have not yet received a full vaccination course in the European Union.

There are still too many individuals at risk of severe COVID-19 infection whom we need to protect as soon as possible. Until most of the vulnerable individuals are protected, we need to keep the circulation of the Delta virus low by strictly adhering to public health measures, which worked for controlling the impact of other variants.

It is very important to progress with the vaccine roll-out at a very high pace. At this stage it becomes crucial that the second vaccination dose is administered within the minimum authorised interval from the first dose, to speed up the rate at which vulnerable individuals become protected. I am aware that it requires a significant effort from public health authorities and the society at large to achieve this goal. But now is the time to walk the extra mile. We have several safe and effective vaccines available and every single infection prevented now through our compliance with public health measures, is a life that can be saved by vaccination.

European Commission
https://ec.europa.eu/commission/presscorner/home/en
No new digest content identified

::::::
Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

World Bank and African Union Team Up to Support Rapid Vaccination for Up to 400 million People in Africa

Working with countries and partners across Africa to quickly expand equitable access to vaccines
WASHINGTON, June 21, 2021— The African Finance Ministers and the World Bank Group met today to fast track vaccine acquisition on the continent and avoid a third wave. In a boost to the African Union’s target to vaccinate 60% of the continent’s population by 2022, the World Bank and the AU announced that they are partnering to support the Africa Vaccine Acquisition Task Team (AVATT) initiative with resources to allow countries to purchase and deploy vaccines for up to 400 million people across Africa.

This extraordinary regional effort complements COVAX and comes at a time of rising COVID-19 cases in the region. World Bank financing is available to support the purchase and deployment of doses secured by AVATT.

"The World Bank is very pleased to support African countries through this partnership with the African Union to quickly provide hundreds of millions of doses," said World Bank Group President David Malpass. "Working together, we can expedite doses to countries and support deployment. Countries urgently need more pathways for acquiring vaccines that match their needs and have early delivery schedules."

“As a result of this joint initiative between the World Bank and African institutions such as the Africa Import Export Bank and the Africa Centre for Disease Control, we now have the capacity to vaccinate at least 400 million people, or 30% of our population of 1.3 billion,” said Strive Masiyiwa, African Union Special Envoy and coordinator of the AVATT. “We really appreciate the extraordinary partnership on this initiative between the AU Vaccine Champion, HE President Cyril Ramaphosa, and David Malpass, the President of the World Bank.”...

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Test batch of the Sputnik V vaccine produced in Iran
Press release, 26.06.2021

Single-dose Sputnik Light vaccine registered in Kyrgyzstan
Press release, 25.06.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
22.06.2021

**Toolkit for Youth Campaign on COVID Appropriate Behaviour, Vaccination drive and Psychosocial well-being**

**Government of India – Press Information Bureau**

*Latest Press Releases*

**PM holds a high level meeting to review progress of vaccination**
Posted on: 26 Jun 2021

**PM lauds record breaking vaccination numbers**
Posted on: 21 Jun 2021

**Indian Council for Medical Research (ICMR)**

https://www.icmr.gov.in/media.html

*Press Releases*

**India achieves milestone of 40 crores COVID-19 Sample Testing : Number of Covid-19 testing laboratories at more than 2600**

:::*

*:::

**China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**NMPA holds meeting to review vaccine regulatory quality management system**
2021-06-25

The National Medical Products Administration (NMPA) held a vaccine regulatory quality management system review meeting on June 15, to summarize the construction and operation of the system, evaluate its appropriateness, effectiveness and adequacy, and make arrangements for the key tasks of the next stage of its construction...

**China-UK drug regulatory cooperation project kicks off**
2021-06-21

The meeting adopted the plan for the China-UK drug regulatory cooperation project in 2021 to push forward technical exchanges in areas of drug review, inspection and post-marketing monitoring for better mutual understanding and deeper cooperation....
Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 22 June 2021

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Pakistan: one WPV1 positive environmental sample
:: Côte d'Ivoire: one cVDPV2 case
:: Nigeria: three cVDPV2 cases
:: South Sudan: two cVDPV2 cases
:: Tajikistan: nine cVDPV2 cases and two cVDPV2 positive environmental samples

WHO/OCHA Emergencies

Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list - WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

Ebola outbreak, Democratic Republic of the Congo, 2021
[Last apparent update: 3 May 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021  [Last apparent update: 3 May 2021]

Coronavirus disease (COVID-19) pandemic  [Last apparent update 25 June 2021; See COVID above]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020  [Last apparent update: 1 June 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018  [Last apparent update: 24 July 2018]

Yemen crisis  [Last apparent update: 12 February 2021]

Syria crisis  [Last apparent update: 18 May 2021]

Somalia crisis  [Last apparent update: 9 May 2018]

Nigeria crisis  [Last apparent update: 9 May 2018]

Ebola outbreak, Democratic Republic of the Congo, 2017  [Last apparent update: 3 May 2021]

Zika virus disease outbreak, 2015-2016  [Last apparent update: 24 Jan 2020]


Iraq crisis  [Last apparent update: 9 Jan 2008]

South Sudan crisis  [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak  [Last apparent update: 21 May 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak  [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic  [Last apparent update: 10 Aug 2010]

 UN OCHA – Current Emergencies

Current Corporate Emergencies
No new digest content identified

WHO & Regional Offices [to 26 Jun 2021]
https://www.who.int/
25 June 2021
News release
At Local Production Forum, WHO and partners highlight key steps to improve access to health technologies

25 June 2021
Departmental news
WHO releases first-ever global guidance for country validation of viral hepatitis B and C elimination
24 June 2021
Departmental news
Demystifying digital health to improve family planning

24 June 2021
Joint News Release
Directors General of WHO, WIPO and the WTO agree on intensified cooperation in support of access to medical technologies worldwide to tackle the COVID-19 pandemic

24 June 2021
Departmental news
WHO announces the update of the “Consolidated Guidelines on HIV, Hepatitis and STI prevention, diagnosis, treatment and care for key populations”

23 June 2021
Departmental news
Putting people first in managing their health: new WHO guideline on self-care interventions

22 June 2021
News release
UNESCO and WHO urge countries to make every school a health-promoting school

21 June 2021
News release
WHO supporting South African consortium to establish first COVID mRNA vaccine technology transfer hub
[See COVID above for detail]

Weekly Epidemiological Record, Vol. 96, No. 25, pp. 241–264
25 June 2021
:: Review of global influenza circulation, late 2019 to 2020, and the impact of the COVID-19 pandemic on influenza circulation

Weekly Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Leaving a legacy after Ebola in Guinea 21 June 2021
It is a quiet morning at an Ebola treatment centre in the outskirts of N’zerekore, a town in the south-east of Guinea. The centre’s triage and reception areas are all empty, and medical staff are relaxed and jovial as they tend to a small handful of patients or catch up on some administrative tasks in the office. Read more »
:: Vaccination boosts Sierra Leone’s Ebola prevention 21 June 2021
While the 2014–2016 deadly Ebola outbreak in West Africa devastated lives and wrecked health services, it also offered pivotal lessons in outbreak control by stoking swift and more effective response as well as driving progress in vaccines and therapeutics.

:: Guinea’s Minister of Health explains what it took to end Ebola 21 June 2021

WHO Region of the Americas PAHO
No new digest content identified

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
No new digest content identified

WHO Eastern Mediterranean Region EMRO
:: Leadership programme on epidemic and pandemic preparedness and response launched 24 June 2021
:: WHO/EU project procures life-saving medicines for children with cancer in Islamic Republic of Iran 22 June 2021
:: Polio vaccination against the odds in Yemen 22 June 2021

WHO Western Pacific Region
No new digest content identified

CDC/ACIP [U.S.] [to 26 Jun 2021]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements

CDC Director Extends the Eviction Moratorium for 30 days
Thursday, June 24, 2021

CDC and HHS Award $200 Million for Disease Intervention Specialist Workforce
Funding awarded to 59 jurisdictions as part of the $1.13 billion investment over the next five years as part of the American Rescue Plan Act of 2021
Monday, June 21, 2021

On June 18, 2021, the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services awarded 59 jurisdictions with $200 million to bolster support and enhance the disease intervention specialists (DIS) workforce. These awards represent the initial funding of the $1.13 billion investment being made over the next five years, consistent with the American Rescue Plan Act of 2021, and will provide these jurisdiction public health programs and CDC with the support needed to expand and leverage the valuable work of DIS.

“Disease intervention specialists have helped halt infectious disease outbreaks in America for decades, and this funding builds upon that expertise for a stronger, healthier America,” said CDC Director Rochelle P. Walensky, MD, MPH. “This critical investment to recruit and train the experts
needed to end this pandemic and prevent the next one is part of our larger effort to rebuild public health infrastructure in the United States to ensure it can protect the health of all Americans for generations to come.”

::::::

**MMWR News Synopsis  Friday, June 25, 2021**
:: HIV Testing Trends Among Persons with Commercial Insurance or Medicaid — United States, 2014–2019
:: COVID-19 Surveillance and Investigations in Workplaces — Seattle and King County, Washington, June 15–November 15, 2020
:: COVID-19 Vaccination Coverage and Intent Among Adults Aged 18–39 Years — United States, March–May 2021 (Early Release June 21, 2021)

::::::

**Coronavirus Disease 2019 (COVID-19)- CDC**
Approximately 50 announcements/reports/data summaries, including:
:: 26 Jun 21
**Overall US COVID-19 Vaccine Distribution and Administration Update as of Sat, 26 Jun 2021 06:00:00 EST**

::::::

**Africa CDC** [to 26 Jun 2021]
http://www.africacdc.org/

![Africa CDC Vaccine Dashboard](https://www.africacdc.org/figs/vaccine_dashboard.png)

<table>
<thead>
<tr>
<th>Africa Vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine Administered (Total)</td>
</tr>
<tr>
<td>Vaccine Administered (1 Dose)</td>
</tr>
<tr>
<td>Vaccine Administered (2 Doses)</td>
</tr>
<tr>
<td>Vaccination Completed</td>
</tr>
</tbody>
</table>
Full scale, interactive dashboard available at: https://africacdc.org/covid-19-vaccination/

China CDC  http://www.chinacdc.cn/en/
CCDC Weekly - Weekly Reports: Current Volume (3)  
2021-06-25 / No. 26
PDF of this issue
:: Preplanned Studies: The Impact of COVID-19 on Tuberculosis Patients’ Behavior of Seeking Medical Care — China, 2020
:: Outbreak Reports: A Tuberculosis Outbreak During the COVID-19 Pandemic — Hubei Province, China, 2020
:: Healthy China: Practical Experiences of Delivering Multidrug-Resistant Tuberculosis Comprehensive Supportive Care Services in China

National Health Commission of the People's Republic of China  [to 26 Jun 2021]
http://en.nhc.gov.cn/
News
June 26: Daily briefing on novel coronavirus cases in China
   On June 25, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 25 new cases of confirmed infections.
China committed to facilitating equitable vaccine distribution globally
2021-06-24

BEIJING -- Delta, the highly infectious coronavirus variant, has been reported in more than 90 countries and regions across the world, highlighting the urgency to mount a herd immunity defense through mass vaccination.

Some developing countries are left in scarcity of vaccines as certain countries have hoarded COVID-19 vaccines several folds more than the amount needed to vaccinate their populations.

To solve the problems of insufficient production capacity and an unbalanced distribution of COVID-19 vaccines, China has put forward its proposals on multiple international forums.

At the 73rd World Health Assembly in May 2020, China made a solemn commitment to making COVID-19 vaccines a "global public good," offering its assistance in promoting fair accessibility to vaccines and affordability for developing countries.

At the Global Health Summit in late May, China called for the rejection of vaccine nationalism in a bid to make vaccines more accessible and affordable in the developing world.

China spares no effort to deliver on its promise in championing international cooperation in fighting the pandemic.

Despite a tight supply and huge domestic demand, China has provided over 350 million doses of COVID-19 vaccines for the international community, including vaccine aid provided for over 80 developing countries and those exported to more than 40 countries.

China has also pledged to provide the first batch of 10 million COVID-19 vaccine doses to COVAX, an initiative aimed to promote equitable access to vaccines initiated by the World Health Organization (WHO)...

National Medical Products Administration – PRC [to 26 Jun 2021]

News
Over 1.1 bln doses of COVID-19 vaccines administered in China
2021-06-25
More than 1.1 billion doses of COVID-19 vaccines have been administered in China as of Thursday, the National Health Commission said on June 25.

NMPA holds meeting to review vaccine regulatory quality management system
2021-06-25
The National Medical Products Administration (NMPA) held a vaccine regulatory quality management system review meeting on June 15, to summarize the construction and operation of the system, evaluate its appropriateness, effectiveness and adequacy, and make arrangements for the key tasks of the next stage of its construction.

China-UK drug regulatory cooperation project kicks off
2021-06-21
The meeting adopted the plan for the China-UK drug regulatory cooperation project in 2021 to push forward technical exchanges in areas of drug review, inspection and post-marketing monitoring for better mutual understanding and deeper cooperation.

::::::
::::::
Organization Announcements

*Editor’s Note:*
Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Paul G. Allen Frontiers Group**  [to 26 Jun 2021]

*News*

**News from The Paul G. Allen Frontiers Group: June 2021**
June 23, 2021
Highlights include a new study by the Allen Discovery Center for Human Brain Evolution, a Science in Sixty video featuring Kathryn Richmond, and more.

**BARDA – U.S. Department of HHS**  [to 26 Jun 2021]
https://www.phe.gov/about/barda/Pages/default.aspx

*News*

No new digest content identified.

**BMGF - Gates Foundation**  [to 26 Jun 2021]
https://www.gatesfoundation.org/ideas/media-center

*Press Releases and Statements*

No new digest content identified.

**Bill & Melinda Gates Medical Research Institute**  [to 26 Jun 2021]
https://www.gatesmri.org/

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

Jun 10, 2021
Penny Heaton @drpennyheaton

It's a bittersweet day as I announce my departure from @GatesMRI to join @JanssenGlobal. I'm grateful for the opportunity to have led such an incredible organization – and I'm excited to lead a team transforming global #vaccine development.

**CARB-X**  [to 26 Jun 2021]
https://carb-x.org/

*News*

No new digest content identified.
Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 26 Jun 2021]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of *Vaccines and Global Health: The Week in Review* are available here.

CEPI – Coalition for Epidemic Preparedness Innovations  [to 26 Jun 2021]
http://cepi.net/
Latest News
No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES  [to 26 Jun 2021]
https://cioms.ch/
Publications
**CIOMS Cumulative Pharmacovigilance Glossary (Version 1.1)**
Year of publication: 2021  Number of pages: 81
This glossary compiles the terms and definitions from published CIOMS pharmacovigilance reports. We welcome all feedback. Please e-mail your recommendations to info@cioms.ch.

**Clinical research in resource-limited settings**
CIOMS
ISBN: 978-929036100-8
Year of publication: 2021  Number of pages: 136
**Description**
Evidence generated through responsible clinical research is one of the major pillars of the advancement of health care. In past decades, there has been tremendous progress in the clinical research and development (R & D) environment globally, with increasing attention being paid to the health needs of people in resource-limited settings, where most of the preventable morbidity and mortality occurs. However, financial, social, ethical and regulatory challenges persist in low- and middle-income countries (LMICs), and most clinical research today is still being conducted in and for high-income countries (HICs). The aim of this report is to provide balanced arguments to promote scientifically sound good quality clinical research in low-resource settings.

The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, non-profit organization with the mission to advance public health through guidance on health research and policy including ethics, medical product development and safety. This report reflects the consensus opinion of the CIOMS Working Group on Clinical Research in Resource-Limited Settings, and was finalized in line with comments received during public consultation. The report is intended for governments and regulatory authorities, the research community and sponsors, as well as international organizations involved in funding or conducting research. The report provides a comprehensive set of recommendations to all major stakeholders. While it builds on the 2016 CIOMS International Ethical Guidelines for Health-related Research Involving Humans, it is not intended to supersede those guidelines.
**Duke Global Health Innovation Center** [to 26 Jun 2021]
https://dukeghic.org/
Friday, June 18, 2021

The G7 underwhelms, with numbers that don’t add up

The G7 began their much-anticipated summit last week with a target to reach 1 billion doses of Covid-19 vaccine in pledged donations for low- and middle-income countries.

---

**EDCTP** [to 26 Jun 2021]
http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.

---

**Emory Vaccine Center** [to 26 Jun 2021]
http://www.vaccines.emory.edu/

Vaccine Center News

No new digest content identified.

---

**European Vaccine Initiative** [to 26 Jun 2021]
http://www.euvaccine.eu/

Latest News

EVI signs MoU with CEPI

21 June 2021

The European Vaccine Initiative (EVI), as coordinator of the TRANSVAC2 vaccine research infrastructure, and the Coalition for Epidemic Preparedness Innovations (CEPI) recently signed a Memorandum of Understanding (MoU), laying the foundation to establish a vaccinology training collaboration with the TRANSVAC2 project.

TRANSVAC2 is dedicated to accelerating and improving vaccine development, by strengthening and disseminating European vaccine expertise. As one of the support activities offered to the scientific community, TRANSVAC2 provides training courses surrounding fundamental and advanced knowledge on a wide-range of vaccine development-related topics. With this MoU, we will boost access of advanced vaccine research and development training to CEPI’s team members, thereby directly supporting CEPI’s important mission to accelerate the development of vaccines against emerging infectious diseases.
EVI welcomes this new partnership agreement with CEPI that attests to the high quality and demand of trainings and courses organised by TRANSVAC2 partners, including University of Oxford, Vaccine Formulation Institute, Wageningen University, Biomedical Primate Research Centre (BPRC), The French Alternative Energies and Atomic Energy Commission (CEA), Fraunhofer (IMI-Fraunhofer), University of Siena (UNISI) and EATRIS.

**FDA** [to 26 Jun 2021]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
*Press Announcements | Selected Details*
**June 25, 2021 - Coronavirus (COVID-19) Update: June 25, 2021**

Today, the FDA is announcing revisions to the patient and provider fact sheets for the Moderna and Pfizer-BioNTech COVID-19 vaccines regarding the suggested increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination. For each vaccine, the Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) has been revised to include a warning about myocarditis and pericarditis and the Fact Sheet for Recipients and Caregivers has been revised to include information about myocarditis and pericarditis. This update follows an extensive review of information and the discussion by CDC’s Advisory Committee on Immunization Practices meeting on Wednesday. The data presented at this meeting reinforced the FDA’s decision to revise the fact sheets and further informed the specific revisions. The warning in the Fact Sheets for Healthcare Providers Administering Vaccines notes that reports of adverse events suggest increased risks of myocarditis and pericarditis, particularly following the second dose and with onset of symptoms within a few days after vaccination. Additionally, the Fact Sheets for Recipients and Caregivers for these vaccines note that vaccine recipients should seek medical attention right away if they have chest pain, shortness of breath, or feelings of having a fast-beating, fluttering, or pounding heart after vaccination. The FDA and CDC are monitoring the reports, collecting more information, and will follow-up to assess longer-term outcomes over several months.


Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug Actemra (tocilizumab) for the treatment of hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is not authorized for use in outpatients with COVID-19.

**June 22, 2021 - Coronavirus (COVID-19) Update: June 22, 2021**

**Fondation Merieux** [to 26 Jun 2021]
http://www.fondation-merieux.org/
*News, Events*
*No new digest content identified*

**Gavi** [to 26 Jun 2021]
https://www.gavi.org/
*News Releases*
Geneva, 24 June 2021 – Global health leaders Gavi, the Vaccine Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria have joined forces with the International Federation of Accountants (IFAC) to contribute to, and support, the implementation of robust accounting practices in the public health sector and to improve overall financial management of donor funds by implementing countries. Through this Memorandum of Understanding (MoU), Gavi, the Global Fund and IFAC seek to strengthen the expertise of accountancy and finance professionals and help close the gaps in accountancy skills in implementing countries, which can impact the reliability and effectiveness of managing and disbursing funds. The MoU builds on a 2011 agreement and aims to optimize the joint efforts of global health partners to maximize the performance of investments and support the sustainability of health programs.

“Gavi has cooperated with IFAC and national accounting organizations for a number of years to ensure sound financial management of the funding we provide to countries – this agreement allows us to go much further with a focus on the health sector, in leveraging the expertise of the accountancy profession to boost transparency, build local skills and capacity to improve overall accounting practices, and build a stronger ethical framework,” Anuradha Gupta, Deputy CEO of Gavi, commented. “That will ultimately bring economic and societal benefits to everyone.”

“Equipping our implementing partners with the right financial management skills is essential to maximize the impact of our investments and contributes to greater results in the fight against HIV, tuberculosis and malaria,” said Adda Faye, Chief Financial Officer at the Global Fund. “We are excited to join efforts with Gavi and IFAC to strengthen financial management, reporting, accountability, and transparency to better serve the societies and people in countries receiving Global Fund investments.”

“Robust and transparent accounting and reporting systems are the bedrock of strong public financial management and are thereby critical to the effectiveness and impact of Gavi and The Global Fund's disbursement of lifesaving funds and resources,” said IFAC President Alan Johnson. “Leveraging our global network and accountancy expertise, this MoU underscores the unique value that IFAC and our member bodies bring to organizations with a shared interest in enhancing the accountancy function to build a resilient and sustainable public health sector that leads to a fairer society for all.”

This work will start with a number of pilot countries in collaboration with local professional accountancy organizations (PAOs). Gavi and the Global Fund will be responsible for funding, selecting beneficiary organizations, and monitoring the implementation of targeted capacity-building activities which include training, establishing and reinforcing accountancy standards, reinforcing ethics and whistle-blowing policies, implementing diversity and inclusiveness policies and helping set up appropriate legal foundations, governance structures, and operational capacity.

Ultimately, this partnership will lead to better integration of Gavi and the Global Fund investments into country systems, better internal controls to reduce fiduciary and financial risks, enhanced absorption of grants and ultimately greater impact.
Gavi allocates US$ 60 million for RBC GAM impact investment bond
:: Gavi is investing in the RBC Global Asset Management’s RBC Impact Bond Strategy, which supports measurable social and environmental progress
:: In recent years, Gavi has substantially expanded its embrace of sustainably focused investments
:: “Our partnership with RBC GAM puts Gavi’s investment resources where its values and mission are,” said Stephen Zinser, the Chair of Gavi’s investment committee

Geneva 21 June 2021 – Gavi, the Vaccine Alliance today announced it is allocating US$ 60 million to support economic development efforts with an aim of reducing poverty, promoting economic prosperity for all and protecting the planet.

In partnership with RBC Global Asset Management (RBC GAM), Gavi is investing in the RBC Impact Bond Strategy, which is dedicated to supporting measurable social and environmental progress through investments in projects like clean water and sanitation, good health and well-being, affordable housing, clean energy, economic equality, and quality education. This investment aims to deliver both competitive risk-adjusted returns and positive social and environmental outcomes.

“Our partnership with RBC GAM puts Gavi’s investment resources where its values and mission are,” said Stephen Zinser, the Chair of Gavi’s investment committee and CEO of Roxbury Asset Management...

GHIT Fund  [to 26 Jun 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 212 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

Global Fund  [to 26 Jun 2021]
News & Stories
News
24 June 2021
Global health leaders Gavi, the Vaccine Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria have joined forces with the International Federation of Accountants (IFAC) to contribute to, and support, the implementation of robust accounting practices in the public health sector and to improve overall financial management of donor funds by implementing countries.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]  [to 26 Jun 2021]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories  [to 26 Jun 2021]
http://www.hillemanlabs.org/
Website reports "under maintenance" at inquiry

**Human Vaccines Project**  [to 26 Jun 2021]
http://www.humanvaccinesproject.org/
No new digest content identified.

**IAVI**  [to 26 Jun 2021]
https://www.iavi.org/newsroom
Latest News
No new digest content identified.

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
Selected Statements, Press Releases, Research
No new digest content identified.

**ICRC**  [to 26 Jun 2021]
Selected News Releases, Statements, Reports
**Sexual Violence, Conflict, and COVID-19: An Invisible Pandemic**
Despite clear legal prohibitions, sexual violence remains widespread during armed conflicts and other situations of violence, as well as in detention. It occurs in various contexts and has grave humanitarian consequences.
24-06-2021 | Article

**The challenges for humanitarian action in today’s conflicts: the perspective from the International Committee of the Red Cross**
Excellencies, colleagues. It is a pleasure to address you today and I extend my warm appreciation to Minister of Defence Sergey Shoygu.
23-06-2021 | Statement

**International Generic and Biosimilar Medicines Association [IGBA]**
https://www.igbamedicines.org/
News
No new digest content identified.

**IFFIm**
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.
Pacific: Vaccination uptake critical as COVID-19 variants spread
Kuala Lumpur/Suva, 23 June 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) urges all adults to get vaccinated in Pacific countries including Fiji as it sets grim national records for COVID-19 infections. Fiji is strug ...
23 June 2021

Red Cross Red Crescent: Humanitarian sector joins forces to tackle ‘existential threat’ of climate change
Geneva, 22 June 2021 – The humanitarian sector has a key role to play in addressing the climate and environment crises that affect people’s lives and livelihoods around the world every day. This means walking the talk in terms of integrating climate sm ...
22 June 2021

Fiji
Fiji TC Yasa: Six months on COVID-19 slows recovery efforts
Kuala Lumpur/Suva, 21 June 2021 – Six months after Cyclone Yasa tore through Fiji, leaving thousands of people homeless, essential movement restrictions to contain the dangerous spread of COVID-19 have delayed recovery efforts. Restrictions, while nece ...
21 June 2021

Institut Pasteur  [to 26 Jun 2021]
Press Info
Press release  22.06.2021
Drug repurposing to counter COVID-19: antiviral activity may be induced by phospholipidosis
Over the past 16 months and against the backdrop of the COVID-19 health crisis, thousands of drugs have been tested with a view to repurpose them to tackle SARS-CoV-2. Many of these drugs have demonstrated potential antiviral activity (23 compounds including hydroxychloroquine, azithromycin, amiodarone and 4 others tested in clinical trials). Given this high number of potential treatments, the University of California San Francisco (UCSF), the Quantitative Biosciences Institute, the Institut Pasteur and Novartis joined forces as part of an international collaboration to demonstrate that in vitro antiviral activity was in fact induced by a mechanism common to all the compounds: phospholipidosis. This research has revealed the importance of systematically testing phospholipidosis as part of the repurposing process, with a view to honing criteria for selecting drugs put forward for clinical trials. The results of the research were published in Science on June 22, 2021...

IOM / International Organization for Migration  [to 26 Jun 2021]
News
UNAIDS, IOM: People on the Move Living with HIV Must Have Access to COVID-19 Vaccines
Geneva – Migrants, refugees, internally displaced as well as crisis-affected and mobile populations who are living with HIV must have equitable access to COVID-19 vaccines, said the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the International Organization for...

**UN Agencies Welcome Relocation of 4,000 Vulnerable Asylum Seekers and Refugees from Greece, Encourage Further Steps Towards Predictable, Systematic European Mechanism**

2021-06-24 22:36

Athens – IOM, the International Organization for Migration, UNHCR, the UN Refugee Agency, and UNICEF the UN Children’s Fund welcomed today (24-06) the relocation of 43 asylum seekers on two flights to France.

**Nearly 14 Million Internally Displaced Persons, Refugees and Migrants Hit Hard by COVID-19 in East and Horn of Africa, New IOM-WFP Study Finds**

2021-06-22 11:59

Nairobi – Nearly 9 million Internally Displaced Persons (IDPs), 4.7 million refugees and asylum-seekers, and hundreds of thousands of migrants in East and Horn of Africa are suffering some of the worst impacts of the COVID-19 pandemic, according to a report from IOM, the...

**UN Statement on the Renewal of Humanitarian Lifeline to Millions of People in North-West Syria**

2021-06-21 17:42

Rome/Geneva/New York – Millions of people are pressed up against the border in an active war zone in north-west Syria and remain in need of humanitarian aid to survive. The UN needs cross-border and cross-line access to reach those most in need.

**IVAC** [to 26 Jun 2021]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

*Updates; Events*

**Webinar: Vaccines, Primary Care, and Public Health—After COVID, What’s Next?**

When: Wednesday, July 7, 2021 from 12:00pm to 1:00pm ET

Join Dr. Tom Frieden, President and CEO of Resolve to Save Lives, for a 60-minute webinar hosted by the International Vaccine Access Center to discuss what roles and strategies vaccines, primary care and public health will play while we prepare for life after COVID-19.

**IVI** [to 26 Jun 2021]

http://www.ivi.int/

*Selected IVI News, Announcements, Events*

*No new digest content identified.*

**JEE Alliance** [to 26 Jun 2021]

https://www.jeealliance.org/

Selected News and Events

*No new digest content identified.*
25 Stakeholder Groups Call on Congressional Leadership to Invest $30 billion over 4 years to Better Protect Americans from Future Pandemics

June 22, 2021 – Today, the Johns Hopkins Center for Health Security joined 24 other stakeholder organizations to submit a letter of support to strongly encourage Congressional leaders to invest $30 billion over 4 years to better protect Americans from future pandemics, as called for in the American Jobs Plan. These funds can create new U.S. jobs in public health, science and technology innovation, and domestic medical countermeasures infrastructure.

Given the devastating consequences of the COVID-19 pandemic, the U.S. should aim to achieve an ambitious but achievable goal of creating a pandemic-free future. Together the 25 stakeholder groups strongly encourage Congress to include this $30 billion investment in a funding vehicle this year...

MSF/Médecins Sans Frontières

Ongoing violence against detained migrants forces MSF to suspend Tripoli detention centre activities
Press Release 22 Jun 2021

Cameroon
People in northwest seek healthcare as MSF denied providing medical services
Press Release 22 Jun 2021

Ethiopia Tigray crisis
Tigray violence scatters people across two countries
Crisis Update 22 Jun 2021

National Academy of Medicine - USA
No new digest content identified.

National Vaccine Program Office - U.S. HHS
No new digest content identified.

NIH
News Releases
**International study of rare childhood cancer finds genetic clues, potential for tailored therapy**
June 24, 2021 — Rhabdomyosarcoma, or RMS, is a rare cancer that affects the muscles and other soft tissues.

**NIH begins study of COVID-19 vaccination during pregnancy and postpartum**
June 23, 2021 — Researchers will evaluate antibody responses in vaccinated participants and their infants.

**NIH study suggests COVID-19 prevalence far exceeded early pandemic cases**
June 22, 2021 — Researchers estimate nearly 17 million undiagnosed cases in the U.S. by mid-July 2020.

**UN OCHA** Office for the Coordination of Humanitarian Affairs [to 26 Jun 2021]
https://www.unocha.org/
Press Releases
No new digest content identified.

**PATH** [to 26 Jun 2021]
https://www.path.org/media-center/
Press Releases
No new digest content identified.

**Rockefeller Foundation** [to 26 Jun 2021]
https://www.rockefellerfoundation.org/
Selected Reports/Press Releases
Jun 23 2021
Press Releases
**New Vaccine Equity Cooperative Launches to Advance Covid-19 Vaccine Access and Readiness**

Latest Initiative from Collaboration of Racial Health Equity-focused Organizations Includes New Online Resource Hub for Community-Based Workforces

BOSTON, Mass. and OAKLAND, Calif. – The Vaccine Equity Cooperative, a new national collaboration of community health-focused organizations, has launched an online resource hub and information platform to support community-based workforces as they work to increase COVID-19 vaccine access and readiness across the U.S during the most challenging stage of the vaccination effort. As communities of color continue to be disproportionately impacted by vaccine misinformation, mistrust and barriers to access, the website provides curated resources and real-time updates vetted by trusted health care, public health and racial equity experts, as well as opportunities to share content and connect in open forums.

While more than half the adults in the U.S. have been vaccinated, the rate of white people receiving at least one vaccine dose is still 1.4 times higher than that of Black people and 1.2 times higher than that of Hispanic people. People with lingering questions about COVID-19 vaccine safety and access are
continuing to turn to trusted local leaders, organizers and health workers in their communities for advice and support about COVID-19 vaccines.

With the country projected to fall short of the Biden administration’s goal of getting 70 percent of American adults at least partially vaccinated by July 4th, supporting local outreach and 1:1 conversations with those facing the most barriers and skepticism will be essential to the success of vaccination efforts, efforts to safely re-open and long-term national public health.

“Community-based and public health workforces have long been underfunded and under-supported, but proved to be absolutely critical to the pandemic response and vaccine rollout,” said Alexandra Quinn, CEO of Health Leads. “The Vaccine Equity Cooperative envisions a world where local workforces have the resources they need – not only to respond to crises, but proactively address ongoing barriers to health. With a goal of enabling racial health equity, our Cooperative will be an ongoing effort to strengthen our public and community health infrastructure through public and private investment, advocacy, and sharing resources and learnings from and with communities across the country.”

Difficulties in accessing accurate information, online registration, language barriers, hard-to-reach vaccination sites and failure of institutions to gain trust are only a few of the factors that have contributed to the disparities in U.S. vaccination rates. While other general population vaccine-related resource hubs exist, the Cooperative’s site offers curated toolkits tailored to community types and drawn from trusted organizations and local leaders.

“Frontline community-based workers and leaders have been the trusted sources and translators of complex health information for generations, but COVID-19 vaccines introduced a host of new data, questions and misinformation,” said Denise Octavia Smith, Executive Director of the National Association of Community Health Workers, a founding partner of the project. “This website helps them navigate readiness and access efforts with community-specific tools and resources from people and organizations that they can trust.”

The Cooperative is encouraging all community-based workforce members to collaborate on the project by giving feedback on published resources, sending questions and requests for information, or sharing new resources and events for publication on the site.

About the Vaccine Equity Cooperative
Visit the resource hub and learn more about the Vaccine Equity Cooperative at www.vaccineequitycooperative.org.

The Vaccine Equity Cooperative is a national collaboration of organizations committed to racial health equity, including Health Leads, CONVINCE USA, National Association of Community Health Workers, Native Ways Federation and Partners In Health. The Cooperative works to increase access to trusted health resources, expand investment in community-based organizations, and strengthen policy in support of community-based and public health workforces. The Cooperative is supported by The Rockefeller Foundation, The JPB Foundation, The W.K. Kellogg Foundation, and The Kresge Foundation. For more information and the Cooperative’s resource hub, visit www.vaccineequitycooperative.org.

Sabin Vaccine Institute  [to 26 Jun 2021]
http://www.sabin.org/updates/pressreleases
UNAIDS [to 26 Jun 2021]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
25 June 2021
Training on data on the location and size estimates of key populations in western and central Africa

21 June 2021
Small steps towards a big goal

21 June 2021
The importance of young people’s sexual and reproductive health and rights to the global HIV response

UNHCR Office of the United Nations High Commissioner for Refugees [to 26 Jun 2021]
Selected News Releases, Announcements
UNHCR calls on states to remove barriers to access to COVID-19 vaccines for refugees
24 June 2021
[See COVID above for detail]

UN agencies welcome relocation of 4,000 asylum seekers and refugees from Greece
IOM, UNHCR and UNICEF jointly encourage further steps towards a predictable, systematic European relocation mechanism.
24 June 2021

UN High Commissioner for Refugees praises Latin America for its commitment to the inclusion of all those in need of protection
23 June 2021
Quito, Ecuador – At the end of a week-long visit to three Latin American countries, UN High Commissioner for Refugees Filippo Grandi applauded the region for its solidarity and commitment to protect refugees, asylum seekers and other displaced people.
“Latin American countries are facing an unprecedented level of displacement,” said Grandi. “Yet, they have stepped up to the challenge by showing unique generosity and dedication to find dignified solutions for those forced to flee.”
The Americas region is home to 20 per cent of the 82.4 million people forcibly displaced globally, including the second-largest external displacement crisis in the world – the 5.6 million refugees and migrants from Venezuela. As Latin America struggles to contain the COVID-19 pandemic, several countries have initiated large-scale regularization programmes to realize the full potential of displaced people and the contribution they can make to their communities.
“Inclusion is one of the most practical and concrete forms of protection. It helps children to get an education, people to receive the medical treatment they need, prevents exploitation and abuse and
supports people to acquire the dignity of self-sustaining work,” explained Grandi. “Inclusion is the new protection.”…

UNICEF [to 26 Jun 2021]
https://www.unicef.org/media/press-releases
Selected Press Releases, Statements
News note 06/25/2021
Geneva Palais briefing note on the worsening situation in Sub Saharan Africa as a result of secondary impacts of COVID-19

This is a summary of what was said by UNICEF spokesperson James Elder – to whom quoted text may be attributed - at today’s press briefing at the Palais des Nations in Geneva

GENEVA, 25 June 2021 - "Sub-Saharan Africa is in the throes of a deadly uptake in COVID-19. At the present rate of infections, the current surge will exceed the previous one within weeks. As more contagious variants spread, vaccines continue to be perilously slow in reaching Africa, and hospitals are pushed beyond capacity.

"Amid it all, the impacts on children continue to be devastating. So as to provide a very quick regional snapshot:
:: In Uganda there has been a 2,800 per cent increase in new COVID19 cases between March and June 2021. The availability of oxygen in Uganda become a life or death situation.
:: Namibia, last week, had the highest death rate in Africa. Hospitals are full and there are not enough oxygen tanks. According to the Ministry of Health, Namibia is experiencing over 1,000 new COVID19 cases each day and 30 deaths. That is a high death rate for a country of 2.5 million people.
:: In the Democratic Republic of the Congo, it’s an equally daunting picture – with low vaccination rates and poor health facilities.
:: And in South Africa a third wave is threatening to be even worse than the previous two, stretching an already strained healthcare system. So far, only 2.5 million people have received at least one vaccination, from a population of around 57 million. And yet that’s one of the higher vaccination rates on the continent.
:: Indeed, if we look at the situation across the world, there have been about 2.7 billion doses administered. Of these, around just 1.5% have been administered on the continent.

"What does all this look like for a child in Sub Saharan Africa?

"It looks like the loss of parents, and grandparents who care for so many children; It looks like less education and more abuse. COVID-19 has meant a devastating blow to education. For instance, UNICEF estimates 9 million children in Eastern and Southern Africa never returned to class as schools started opening; And now schools that re-opened are starting to close again; "it looks – and feels – like more anxiety and stress for children, as isolation, confinement, and loss of income take their toll…

Unitaid [to 26 Jun 2021]
https://unitaid.org/
Featured News
Unitaid’s Executive Board meets to discuss strategic direction in an evolving global health landscape at 38th meeting
Geneva, 18 June 2021 – The Executive Board recognized Unitaid’s leadership and agility in responding to COVID-19 and discussed new challenges and opportunities facing the organization during its 38th meeting, held virtually from 16th to 18th June.

Unitaid’s board reaffirmed its commitment to its core work and explored lessons learned from the pandemic response and ways its innovative model and expertise could lend itself to additional contexts.

As Unitaid continues its strategy development process for 2022-2026, key among the considerations discussed was how to define ambitions and priorities in a way that allows enough flexibility to ensure success in an increasingly challenging global health environment...

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 26 Jun 2021]
https://www.vaccineacceptance.org/
Announcements
*No new digest content identified.*

**Vaccine Confidence Project** [to 26 Jun 2021]
http://www.vaccineconfidence.org/
News, Research and Reports
**Coronavirus global impact**
Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 26 Jun 2021]
http://www.chop.edu/centers-programs/vaccine-education-center
News
*No new digest content identified.*

**Wellcome Trust** [to 26 Jun 2021]
https://wellcome.ac.uk/news
News and reports
**Explainer**
**What treatments are working for Covid-19?**
From existing antivirals to new antibody therapeutics – researchers are working tirelessly to find the best drugs to treat Covid-19.
23 June 2021

**The Wistar Institute** [to 26 Jun 2021]
Press Releases
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 26 Jun 2021]
https://www.wfpha.org/
World Bank [to 26 Jun 2021]
Selected News, Announcements

US$30m Boost for PNG’s COVID-19 Response
World Bank announces additional support for COVID-19 response and vaccine rollout PORT MORESBY, June 25, 2021 – The World Bank has approved an additional US$30 million (approximately PGK70m) in funding...
Date: June 25, 2021 Type: Press Release

Additional Financing Support by the Green Climate Fund to Help Strengthen Climate Resilience in Central Asia
WASHINGTON, June 24, 2021 — The World Bank, as an accredited entity for the Green Climate Fund (GCF), approved today additional financing totaling $19 million for the Climate Adaptation and Mitigation...
Date: June 24, 2021 Type: Press Release

New $200 Million World Bank Project to Support COVID-19 Relief, Build Resilience Against Future Economic Shocks in Cambodia
WASHINGTON, June 24, 2021 – Cambodia’s efforts to combat the ongoing COVID-19 pandemic and begin its journey toward economic recovery were given a boost today by World Bank’s Board of Executive Directors...
Date: June 24, 2021 Type: Press Release

World Bank Approves US$100 Million for Barbados’ COVID-19 Response and Recovery
WASHINGTON, June 24, 2021 – The World Bank Board of Executive Directors approved today a US$100 million COVID-19 Response and Recovery Development Policy Loan for Barbados. The operation will support the...
Date: June 24, 2021 Type: Press Release

New Grant to Sustain Afghanistan’s Reforms toward COVID-19 Recovery
Washington, June 24, 2021— The World Bank Board of Executive Directors today approved a $132 million grant from the International Development Association (IDA) to help Afghanistan continue implementing...
Date: June 24, 2021 Type: Press Release

Remarks by World Bank Group President David R. Malpass: Avoiding a Lost Decade in Latin America and the Caribbean (LAC)
Thank you, Maria, the Andean American Associations, and all participants throughout the Latin American and Caribbean regions. I also want to thank Juana Caicedo, President of the Ecuadorean American Association...
Date: June 23, 2021 Type: Speeches and Transcripts

US$63.75 Million Additional Financing to Support COVID-19 Vaccination in Jordan
Washington DC, June 23, 2021 – The World Bank approved on June 16, 2021, US$63.75 million in additional financing for the ongoing Jordan COVID-19 Emergency Response project to support Jordan’s efforts...
Date: June 23, 2021 Type: Press Release

World Bank and African Union Team Up to Support Rapid Vaccination for Up to 400 million People in Africa
Working with countries and partners across Africa to quickly expand equitable access to vaccines
WASHINGTON, June 21, 2021— The African Finance Ministers and the World Bank Group met today to fast...
Date: June 21, 2021 Type: Press Release

World Customs Organization – WCO [to 26 Jun 2021]
http://www.wcoomd.org/
Latest News – Selected Items
26 June 2021
WCO Council renews support for the Secretariat in preparation for a post-pandemic world
Heads of Delegation of some 130 World Customs Organization (WCO) Member Customs administrations took part in the virtual meeting of the 138th Session of the WCO Council, held from 24 to 26 June 2021. As the world is bracing for recovery with a glimmer of optimism emerging from the global effort regarding vaccinations, this session focused on Capacity Building, Rules of Origin, Valuation, Nomenclature and Classification, Compliance and Trade Facilitation as well as budgetary and financial matters...

World Organisation for Animal Health (OIE) [to 26 Jun 2021]
Press Releases
No new digest content identified.

::::

ARM [Alliance for Regenerative Medicine] [to 26 Jun 2021]
Press Releases - Alliance for Regenerative Medicine (alliancerm.org)
Selected Press Releases
No new digest content identified.

BIO [to 26 Jun 2021]
Press Releases
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 26 Jun 2021]
http://www.dcvmn.org/
News; Upcoming events
ICBA – International Council of Biotechnology Associations  [to 26 Jun 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 26 Jun 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications

New Non-State Actors Alliance calls on behalf of patients, industry for urgent action to set
22 June – Paris/Geneva/London – Ministers of Health from four African countries (Algeria, Democratic Republic of Congo, Egypt and Cabo Verde), representatives from international organizations, patient groups and the pharmaceutical industry reiterated today at a high-level roundtable event the urgency of establishing a regulatory authority across Africa, especially in the context of the COVID-19 pandemic. The current fragmented regulatory systems across the continent are making it difficult to mount an appropriate response.

Ministers of Health and roundtable participants outlined the first areas of work for the AMA and agreed that it has the unique opportunity to become one of the most efficient and modern regulatory systems in the world. Once established, it will perform a vital task in overseeing rapid and effective market authorisation of safe, quality, effective and accessible vaccines, medicines, and health devices to control and treat disease across Africa to robust regulatory standards. Crucially, it will foster reliance and regulatory harmonization across the continent. In practice, this means that national regulatory authorities will be able to build on the work done by counterparts in other countries, significantly cutting down the time it takes for medicines, vaccines or diagnostics to reach the market. For many countries, the AMA also holds the promise of driving industrial and economic growth, through encouraging the development of local pharmaceutical industry and the establishment of centres of excellence for research across the continent.

But while commitment to the AMA mission and vision is strong, it has not translated into concrete actions. A new cross-stakeholder alliance announced at the roundtable, the African Medicines Agency Treaty Alliance (AMATA), will seek to push for rapid ratification of the Treaty, as well as meaningful engagement with patients, industry and other relevant parties once the Agency becomes operational...

Biopharmaceutical CEO Brussel meeting with EU leaders focuses on equitable access to tackle COVID-19, fostering
Brussels, 22 June 2021 – The Biopharmaceutical CEO Roundtable (BCR), which represents the world’s leading biopharmaceutical companies, held their first face-to-face meeting since December 2019 in Brussels on Monday 21 and Tuesday 22 June, to discuss global health challenges and public health policies impacting biomedical innovation.

The fourteen biopharmaceutical industry CEOs who attended in person represent a global industry which is heavily invested in Europe, as key players in the research and development ecosystem, local economies and with health care systems. Their programme...covered a range of topics, including the development and scaling up of COVID-19 vaccines and how to foster an environment that invests in innovation. The CEOs explained the incredible innovations coming down the pipeline for patients, such as combination therapies, advanced therapies and Artificial Intelligence guided therapy.
The multifaceted root cause of unavailability and delay to innovative medicines were discussed, and the need to find solutions to reduce the time before patients have access to innovative medicines. The group tabled a number of proposals including the establishment of an industry portal targeting European access hurdles reflecting the shared aspiration of companies to file pricing and reimbursement applications within 2 years from the granting of the marketing authorization. The CEO delegation made concrete proposals to ensure equity of access and solidarity across EU member states, by means of equity-based tiered pricing, which would require an intergovernmental framework for it to be implementable and effective. There was clearly a shared commitment to ensure safe and efficacious innovative products reach the market and patients, enabled by a first-class regulatory system. The EU’s regulatory system, which stood up well to the pandemic challenges, could remove the bottlenecks and catch up with regulatory systems in other parts of the world in terms of speed and flexibility of assessment by rationalising the decision making (expertise based) and reducing interfaces...

PhRMA  [to 26 Jun 2021]
http://www.phrma.org/

Latest News
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
PhRMA released a new report exploring the 829 medicines in development that aim to address the diseases and conditions that affect racial and ethnic communities at a higher rate.

Blog Post

* * * * *

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 12, 2020 Issue 2
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 23, Number 6: E435-504  June 2021
https://journalofethics.ama-assn.org/issue/transgenerational-trauma
Transgenerational Trauma
One thing that makes trauma transgenerational is narrative. Narrative, for example, is what makes a Confederate flag from 1865 flint for insurrection in 2021. Consequences of global and domestic insults, such as slavery and forced migration, have long ramified intergenerationally in communities, families, and individuals' bodies. Legacies of trauma travel in stories across places and over time, and their effects include health status inequity and cumulative stress embodiment. Transmission of historically entrenched patterns of oppression also influence persons’ lived experiences of marginalization, convey health risk, and can play out during clinical encounters.

American Journal of Infection Control
June 2021 Volume 49 Issue 6 p657-856
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
June 2021 Volume 60 Issue 6 p737-884
http://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
June 2021 111(6)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml
[Reviewed earlier]

Annals of Internal Medicine
June 2021 Volume 174, Issue 6
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 295 June 2021
[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
Social and ethical issues of poor quality and poor use of medical products

Access to water, sanitation and hygiene services in health facilities in sub-Saharan Africa 2013–2018: Results of health facility surveys and implications for COVID-19 transmission

Principles for pandemics: COVID-19 and professional ethical guidance in England and Wales

Who should be tested in a pandemic? Ethical considerations
In the initial phase of the Covid-19 pandemic, difficult decisions had to be made on the allocation of testing resources. Similar situations can arise in future pandemics. Therefore, careful consideration of...

Authors: Sven Ove Hansson, Gert Helgesson and Niklas Juth
Citation: BMC Medical Ethics 2021 22:76
Content type: Review
Published on: 22 June 2021

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 26 Jun 2021)
[No new digest content identified]

BMC Pregnancy and Childbirth
http://www.biomedcentral.com/bmcpregnancychildbirth/content
(Accessed 26 Jun 2021)
[No new digest content identified]

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 26 Jun 2021)
**Disparity in the quality of COVID-19 data reporting across India**
Transparent and accessible reporting of COVID-19 data is critical for public health efforts. Each Indian state has its own mechanism for reporting COVID-19 data, and the quality of their reporting has not been...

Authors: Varun Vasudevan, Abeynaya Gnanasekaran, Varsha Sankar, Siddarth A. Vasudevan and James Zou
Citation: BMC Public Health 2021 21:1211
Content type: Research article
Published on: 24 June 2021

**Investigation of the relationships between perceived causes of COVID-19, attitudes towards vaccine and level of trust in information sources from the perspective of Infodemic: the case of Turkey**
The main purpose in this study carried out from the perspective of infodemic was to investigate the relationships between individuals’ perceived causes of COVID-19, their attitudes towards vaccine and their le...

Authors: Şemsi Nur Karabela, Filiz Coşkun and Haydar Hoşgör
Citation: BMC Public Health 2021 21:1195
Content type: Research
Published on: 23 June 2021

BMC Research Notes
http://www.biomedcentral.com/bmcreresnotes/content
COVID


Ravi Jhaveri
Published online: March 23, 2021
Abstract
The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic.

Clinical Trials
Volume 18 Issue 3, June 2021
https://journals.sagepub.com/toc/ctja/18/2
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 26 Jun 2021]
[No new digest content identified]

Contemporary Clinical Trials
Volume 105 June 2021
[New issue; No digest content identified]

The CRISPR Journal
Volume 4, Issue 3 / June 2021
https://www.liebertpub.com/toc/crispr/4/3
Research Articles  Free
A Decade of CRISPR Gene Editing in China and Beyond: A Scientometric Landscape
Wuyuan Zhou, et al
Pages:313–320
Published Online:16 June 2021
https://doi.org/10.1089/crispr.2020.0148

Review Article  Free
Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing
Sarah Balderston, et a;
Pages:400–415
Published Online:16 June 2021
https://doi.org/10.1089/crispr.2020.0137

Current Genetic Medicine Reports
Volume 9, issue 2, June 2021
Current Opinion in Infectious Diseases
June 2021 - Volume 34 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 21, Issue 2  June 2021
https://onlinelibrary.wiley.com/toc/14718847/current
Special Issue: Conscientious objection to termination of pregnancy in the global south: legal and ethical challenges
Issue Edited by: Anita Kleinsmidt

Development in Practice
Volume 31, Issue 4, 2021
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 15 - Issue 2  - April 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[New issue; No digest content identified]

Disasters
Volume 45, Issue 3  Pages: 499-737  July 2021
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 22  Issue 6  4 June 2021
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]
Psychobehavioral Responses and Likelihood of Receiving COVID-19 Vaccines during the Pandemic, Hong Kong [PDF - 1.98 MB - 9 pages]
K. O. Kwok et al.

Epidemics
Volume 35  June 2021
[Reviewed earlier]

Epidemiology and Infection
Volume 149 - 2021
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 43, Issue 3  Pages: 1-44  May–June 2021
https://onlinelibrary.wiley.com/toc/25782363/current
Underrepresented populations in clinical research  Human infection challenge trials
[Reviewed earlier]

The European Journal of Public Health
Volume 31, Issue 2, April 2021
https://academic.oup.com/eurpub/issue/31/2
[Reviewed earlier]

Expert Review of Vaccines
Vol 20 (3) 2021
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Forum for Development Studies
Volume 48, 2021 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]
Managing borders during public health emergencies of international concern: a proposed typology of cross-border health measures
Authors: Kelley Lee, Karen A. Grépin, Catherine Worsnop, Summer Marion, Julianne Piper and Mingqi Song
Content type: Research
21 June 2021
Localisation and local humanitarian action
by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.
Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 17, Issue 5, 2021
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

Infectious Agents and Cancer
http://www.infectagentscancer.com/content
[Accessed 26 Jun 2021]
[No new digest content identified]

Infectious Diseases of Poverty
http://www.idpjourn.com/content
[Accessed 26 Jun 2021]
[No new digest content identified]

International Health
Volume 13, Issue 3, May 2021
https://academic.oup.com/inthealth/issue/13/3
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol 8, No 5 (2021) May 2021
https://www.ijcmph.com/index.php/ijcmph/issue/view/76
[Reviewed earlier]

International Journal of Epidemiology
Volume 50, Issue 2, April 2021
https://academic.oup.com/ije/issue
[Reviewed earlier]

International Journal of Human Rights in Healthcare
Volume 14 Issue 1 2021
https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases
Volume 107 p1-310
https://www.ijidonline.com/current
Original Investigation

**US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021**

Isaac See, MD; John R. Su, MD, PhD, MPH; Allison Lale, MD, MPH; et al.


This study describes the reported US cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia following vaccination with Ad26.COV2.S, the COVID-19 vaccine produced by Janssen/Johnson & Johnson.

Editorial

**Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine**

Ruth A. Karron, MD; Nigel S. Key, MD; Joshua M. Sharfstein, MD

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Yoel Angel, MD, MBA; Avishay Spitzer, MD; Oryan Henig, MD; et al.


This cohort study estimates the association between Pfizer-BioNTech BNT162b2 vaccination and symptomatic and asymptomatic SARS-CoV-2 infections among health care workers more than 7 days after receipt of a second vaccine dose.

Research Letter

**Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce**

Li Tang, PhD; Diego R. Hijano, MD, MSc; Aditya H. Gaur, MD, MBBS; et al.


This study aims to describe an association between the Pfizer-BioNTech (BNT162b2) vaccine and decreased risk of symptomatic and asymptomatic infections with SARS-CoV-2 in hospital employees.

Viewpoint

**When Vaccine Apathy, Not Hesitancy, Drives Vaccine Disinterest**

Stacy Wood, PhD; Kevin Schulman, MD


This Viewpoint explains how vaccine apathy rather than hesitancy may lead to population undervaccination, and uses marketing principles to explain how public health messaging might differ to persuade apathetic persons to be immunized to achieve more widespread COVID-19 protection.
JAMA Network
COVID-19 Update  June 26, 2021
These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics
June 2021, Vol 175, No. 6, Pages 553-652
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

JBI Evidence Synthesis
June 2021 - Volume 19 - Issue 6
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Adolescent Health
Volume 68  Issue 6  p1025-1222
https://www.jahonline.org/current
[Reviewed earlier]

Journal of Artificial Intelligence Research
Vol. 71 (2021)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 46, issue 3, June 2021
[Reviewed earlier]

Journal of Development Economics
Volume 151  June 2021
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 16 Issue 1-2, February-April 2021
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]
The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...
Journal of Infectious Diseases
Volume 223, Issue 9, 1 May 2021
https://academic.oup.com/jid/issue/223/9
[Reviewed earlier]

Journal of Medical Ethics
June 2021 - Volume 47 - 6
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 8, Issue 2 (2021)
https://digitalrepository.aurorahealthcare.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
Volume 234  p1-296
http://www.jpeds.com/current
Original Articles
Changes in Strength of Recommendation and Perceived Barriers to Human Papillomavirus Vaccination: Longitudinal Analysis of Primary Care Physicians, 2008-2018
Jessica R. Cataldi, et al
Published online: March 06, 2021
p149-157.e3

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 26 Jun 2021]
[No new digest content identified]

Journal of Public Health Management & Practice
May/June 2021 - Volume 27 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 42, issue 2, June 2021
[Reviewed earlier]
Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
June 2021  Volume 18  Issue 179
https://royalsocietypublishing.org/toc/rsif/current
[Reviewed earlier]

Journal of Travel Medicine
Volume 28, Issue 4, May 2021
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
May 2021; Volume 95, Issue 10
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Jun 26, 2021  Volume 397  Number 10293  p2439-2536, e17-e19
https://www.thelancet.com/journals/lancet/issue/current

*Comment*
**The need for a global COVID-19 maternal immunisation research plan**
Azucena Bardají, Esperança Sevene, Clare Cutland, Clara Menéndez, Saad B Omer, Teresa Aguado, Flor M Muñoz

*Clinical Picture*
**SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban**
Katharina Guetl, Thomas Gary, Reinhard B Raggam, Johannes Schmid, Albert Wölfler, Marianne Brodmann

The Lancet Child & Adolescent Health
Jun 2021  Volume 5  Number 6  p385-458, e19-e27
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Jun 2021  Volume 3  Number 6  e330-e407
**World Bank grants for global vaccination — why so slow?**

International financial institutions say that vaccines are the highest-return investment on Earth — it is past time for them to pay up.

**Article | 10 May 2021**

**Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses**

Immunization of macaques with nanoparticle-conjugated receptor-binding domain of SARS-CoV-2 adjuvanted with 3M-052 and alum results in cross-neutralizing antibodies against bat coronaviruses, SARS-CoV and SARS-CoV-2 variants, and may provide a platform for developing pan-coronavirus vaccines.

Kevin O. Saunders, Esther Lee, Barton F. Haynes

---

**Nature Biotechnology**

Volume 39 Issue 6, June 2021

https://www.nature.com/nbt/volumes/39/issues/6

[Reviewed earlier]

**Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms

(Accessed 26 Jun 2021)

[No new digest content identified]

**Nature Genetics**

Volume 53 Issue 6, June 2021

https://www.nature.com/ng/volumes/53/issues/6

[Reviewed earlier]

**Nature Human Behaviour**

Volume 5 Issue 6, June 2021

https://www.nature.com/nathumbehav/volumes/5/issues/6

[Reviewed earlier]

**Nature Medicine**

Volume 27 Issue 6, June 2021

https://www.nature.com/nm/volumes/27/issues/6

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 22 Issue 6, June 2021
https://www.nature.com/nrg/volumes/22/issues/6
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 21 Issue 6, June 2021
https://www.nature.com/nri/volumes/21/issues/6
[Reviewed earlier]

**Nature Reviews Drug Discovery**
Volume 20 Issue 6, June 2021
https://www.nature.com/nrd/volumes/20/issues/6
[Reviewed earlier]

**New England Journal of Medicine**
June 24, 2021  Vol. 384  No. 25
http://www.nejm.org/toc/nejm/medical-journal
*Perspective*
**Missing the Point — How Primary Care Can Overcome Covid-19 Vaccine “Hesitancy”**
List of authors. Scott Ratzan, M.D., M.P.A., Eric C. Schneider, M.D., Hilary Hatch, Ph.D., and Joseph Cacchione, M.D.

**Pediatrics**
Vol. 147, Issue 6  1 Jun 2021
https://pediatrics.aappublications.org/
[Reviewed earlier]

**PharmacoEconomics**
Volume 39, issue 6, June 2021
*Themed issue: Economic Burden of Major Depressive Disorders*
[Reviewed earlier]

**PLoS Genetics**
https://journals.plos.org/plosgenetics/
(Accessed 26 Jun 2021)
[No new digest content identified]

**PLoS Medicine**
http://www.plosmedicine.org/
(Accessed 26 Jun 2021)
Introduction

In February 2021, an outbreak of Ebola virus disease (EVD) was declared in the N’Zérékoré prefecture, located in the southeastern area of Guinea known as “Forest Guinea” [1]. This region is where the 2013 to 2016 West African epidemic—the largest Ebola epidemic to date—started. In the aftermath, Forest Guinea gained the status of a high-risk region for EVD and other viral haemorrhagic fevers [2]. Consequently, outbreak surveillance and preparedness planning have focused on preparing for a recurrence, such as the 2021 resurgence of Ebola.

Surveillance efforts aim for rapid containment through early detection, specific treatments, and an efficient vaccine. In fact, efforts deployed in the region appear to have detected the current resurgence within a time frame of somewhat less than 1 month. Local communities view the current response through the lens of the earlier outbreak and the preparedness efforts that followed. The response to the 2013 to 2016 epidemic in Forest Guinea was characterised by deep mistrust and violence. In its aftermath, preparedness efforts have been met with scepticism in the population, including healthcare workers, with regard to the ability of the public health system being able to manage future outbreaks effectively...

Knowledge, attitude/perception, and practice related to seasonal influenza vaccination among caregivers of young Thai children: A cross-sectional study
Perceived enablers and barriers of community engagement for vaccination in India: Using socioecological analysis
Tapati Dutta, Jon Agley, Beth E. Meyerson, Priscilla A. Barnes, Catherine Sherwood-Laughlin, Jill Nicholson-Crotty
Research Article | published 25 Jun 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0253318

Determinants of individuals’ belief in fake news: A scoping review determinants of belief in fake news
Kirill Bryanov, Victoria Vziatysheva
Research Article | published 24 Jun 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0253717

Determinant of intention to receive COVID-19 vaccine among school teachers in Gondar City, Northwest Ethiopia
Simegnew Handebo, Maereg Wolde, Kegnie Shitu, Ayenew Kassie
Research Article | published 24 Jun 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0253499

Success of community approach to HPV vaccination in school-based and non-school-based settings in Haiti
Cynthia Riviere, Tatiana Bell, Yonie Cadot, Christian Perodin, Benedict Charles, Claudin Bertil, Jazreel Cheung, Shalmali Bane, Hoi Ching Cheung, Jean William Pape, Marie Marcelle Deschamps
Research Article | published 24 Jun 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0252310

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 26 Jun 2021]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America
June 08, 2021; vol. 118 no. 23
https://www.pnas.org/content/118/23
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 36 - Issue 3 - June 2021
Preventive Medicine
Volume 147  June 2021
[Reviewed earlier]

Proceedings of the Royal Society B
30 June 2021  Volume 288  Issue 1953
https://royalsocietypublishing.org/toc/rspb/current
[Reviewed earlier]

Public Health
Volume 194  Pages 1-274 (May 2021)
[Reviewed earlier]

Public Health Ethics
Volume 13, Issue 3, November 2020
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 136 Issue 4, July/August 2021
https://journals.sagepub.com/toc/phrg/136/4
[Reviewed earlier]

Qualitative Health Research
Volume 31 Issue 7, June 2021
http://qhr.sagepub.com/content/current
[Reviewed earlier]

Research Ethics
Volume 17 Issue 2, April 2021
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
21 Jun 2021
Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
Original research | English |

21 Jun 2021
Patient- and provider-related factors in the success of multidrug-resistant tuberculosis treatment in Colombia*
Original research | English |

Risk Analysis
Volume 41, Issue 6  Pages: 843-1045  June 2021
https://onlinelibrary.wiley.com/toc/15396924/current
[New issue; No digest content identified]

Risk Management and Healthcare Policy
[Accessed 26 Jun 2021]
Review
The Willingness to Receive COVID-19 Vaccine and Its Associated Factors: “Vaccination Refusal Could Prolong the War of This Pandemic” – A Systematic Review
Wake AD
Risk Management and Healthcare Policy 2021, 14:2609-2623
Published Date: 21 June 2021

Science
25 June 2021  Vol 372, Issue 6549
http://www.sciencemag.org/current.dtl
In Depth
For WHO leader, a ‘feeling that we’re failing’
By Jon Cohen
Science25 Jun 2021 : 1376-1377 Full Access
Tedros Adhanom Ghebreyesus had expected more social responsibility in the face of a global crisis. Few have spoken out as forcefully against the global disparity in COVID-19 vaccine distribution as Tedros Adhanom Ghebreyesus, director-general of the World Health Organization (WHO). Tedros, as he prefers to be called, has labeled the inequity “vaccine apartheid” and a “catastrophic moral failure” that has led to a “two-track pandemic.” A global procurement scheme by WHO and other parties to
supply vaccines to poorer countries, the COVID-19 Vaccines Global Access (COVAX) Facility, has not had much impact so far.

Reports

**mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection**
Science25 Jun 2021 : 1413-1418 Open Access
- Previous infection results in enhanced vaccine-induced immune protection against variant B.1.351 and other variants.

**Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose**
Science25 Jun 2021 : 1418-1423 Open Access
- Previous infection results in enhanced variant cross-protective T and B cell responses to a single BNT162b2 vaccine dose.

**Science Translational Medicine**
23 June 2021 Vol 13, Issue 599
https://stm.sciencemag.org/
[New issue; No digest content identified]

**Social Science & Medicine**
Volume 278 June 2021
[Reviewed earlier]

**Systematic Reviews**
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 26 Jun 2021]
[No new digest content identified]

**Theoretical Medicine and Bioethics**
Volume 41, issue 5-6, December 2020
[Reviewed earlier]
**Travel Medicine and Infectious Diseases**
Volume 41  May–June 2021
[Reviewed earlier]

**Tropical Medicine & International Health**
Volume 26, Issue 6  Pages: i-iv, 609-714  June 2021
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

**Vaccine**
Volume 39, Issue 25  Pages 3311-3454 (8 June 2021)
Short communication  Full text access
COVID-19 vaccine hesitancy among persons living in homeless shelters in France
C. Longchamps, S. Ducarroz, L. Crouzet, N. Vignier, ... M. Melchior
Pages 3315-3318

Short communication  Full text access
Childhood immunization during the COVID-19 pandemic in Texas
Tasmiah Nuzhath, Kobi V. Ajayi, Qiping Fan, Peter Hotez, ... Annette K. Regan
Pages 3333-3337

Research article  Open access
Immunogenicity and safety of a tetravalent dengue vaccine and a bivalent HPV vaccine given concomitantly or sequentially in girls aged 9 to 14 years in Mexico
Jose Luis Arredondo, Sandra Maria Villagomez Martinez, Maria Concepcion Morales, Stephanie Meyer, ... Cesar Mascarenas
Pages 3388-3396

Research article  Full text access
Missed childhood immunizations during the COVID-19 pandemic in Brazil: Analyses of routine statistics and of a national household survey
Mariangela F. Silveira, Cristian T. Tonial, Ana Goretti K. Maranhão, Antonia M.S. Teixeira, ... Cesar G. Victora
Pages 3404-3409

Research article  Open access
Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data
Gloria Ikilezi, Steven D Bachmeier, Ian E Cogswell, Emilie R Maddison, ... Angela E Micah
Pages 3410-3418

Research article  Open access
Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey
Alison M. Kraigsley, Kristine A. Moore, Amanda Bolster, Maya Peters, ... Joseph S. Bresee
Pages 3419-3427

Research article Abstract only
Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood
Beth A. Glenn, Narissa J. Nonzee, Lina Tieu, Bettina Pedone, ... Roshan Bastani
Pages 3435-3444

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 26 Jun 2021)
Open Access Article
Psychological Determinants of COVID-19 Vaccine Acceptance among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine Conspiracy Beliefs Scales
by Mariam Al-Sanafi and Malik Sallam
Vaccines 2021, 9(7), 701; https://doi.org/10.3390/vaccines9070701 - 25 Jun 2021
Abstract
Acceptance of coronavirus disease 2019 (COVID-19) vaccination appears as a decisive factor necessary to control the ongoing pandemic. Healthcare workers (HCWs) are among the highest risk groups for infection. The current study aimed to evaluate COVID-19 vaccine acceptance among HCWs in Kuwait, with [...] 

Open Access Article
Modeling the Impact of COVID-19 Vaccination in Lebanon: A Call to Speed-Up Vaccine Roll Out
by Ghina R. Mumtaz, Fadi El-Jardali, Mathilda Jabbour, a Harb, aith J. Abu-Raddad and Monia Makhoul
Vaccines 2021, 9(7), 697; https://doi.org/10.3390/vaccines9070697 - 25 Jun 2021
Abstract
Four months into the SARS-CoV-2 vaccination campaign, only 10.7% of the Lebanese population have received at least one dose, raising serious concerns over the speed of vaccine roll-out and its impact in the event of a future surge. Using mathematical modeling, we assessed [...] 

Open Access Article
Predictors of Intention to Vaccinate against COVID-19 in the General Public in Hong Kong: Findings from a Population-Based, Cross-Sectional Survey
by Elsie Yan, aniel W. L. Lai and Vincent W. P. Lee
Vaccines 2021, 9(7), 696; https://doi.org/10.3390/vaccines9070696 - 25 Jun 2021
Abstract
Vaccination is one of the most effective ways to stop the spread of COVID-19. Understanding factors associated with intention to receive COVID-19 vaccines is the key to a successful vaccination programme. This cross-sectional study explored the rate of vaccination intention and identified its [...] 

Open Access Article
Characteristics of Healthcare Workers Vaccinated against Influenza in the Era of COVID-19

Abstract
Understanding the potential impact of COVID-19 on receiving influenza vaccination among healthcare workers (HCWs) is of utmost importance. The purposes of the present cross-sectional study were to describe the characteristics and to explore the predictors of receiving influenza vaccination among a large cohort [...]

Value in Health
Volume 24 Issue 6 p753-916
https://www.valueinhealthjournal.com/current
[Reviewed earlier]

* * * * *

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 26 Jun 2021
[No new, unique, relevant content]

BBC
http://www.bbc.co.uk/
Accessed 26 Jun 2021
[No new, unique, relevant content]

The Economist
http://www.economist.com/
Accessed 26 Jun 2021
[No new, unique, relevant content]
**Financial Times**
https://www.ft.com/
News in-depth
Indian economy
India’s stricken countryside threatens to undermine recovery
June 27, 2021

Coronavirus latest: Brazil’s Covid inquiry hears testimony over controversial vaccine deal
Brazil’s Covid inquiry hears testimony over controversial vaccine deal
June 25, 2021

Coronavirus latest: Almost half of employed adults in Britain commuting, ONS finds
Israel to reimpose mask requirement despite vaccine success
June 25, 2021

**Forbes**
http://www.forbes.com/
Accessed 26 Jun 2021
8 hours ago

CDC: 4,115 Fully Vaccinated Have Been Hospitalized Or Died With Breakthrough Covid-19 Infections
Although the Covid-19 vaccines offer very good protection, they are not perfect. Covid-19 infections, hospitalizations, and deaths can still occur.
By Bruce Y. Lee Senior Contributor

Breaking /
Jun 25, 2021

WHO Urges Fully Vaccinated People To Continue Wearing Masks As Delta Variant Spreads—But No Word From CDC
“People cannot feel safe just because they had the two doses” in areas where community transmission is high, one official said.
By Alison Durkee Forbes Staff

**Foreign Affairs**
http://www.foreignaffairs.com/
Accessed 26 Jun 2021
[No new, unique, relevant content]

**Foreign Policy**
http://foreignpolicy.com/
Accessed 26 Jun 2021
Review
The First Draft Account of the U.K.’s COVID-19 Catastrophe Is Damning
A new book gives the backstory of a dysfunctional early response.
By Jamie Maxwell, a political journalist in Glasgow, Scotland.

Argument
Demands for a Lab Leak Investigation Are a Dangerous Distraction
U.S.-China cooperation is vital for global health efforts.
By Deborah Seligsohn, an assistant professor of political science at Villanova University.
June 18, 2021

New Yorker
http://www.newyorker.com/
Accessed 26 Jun 2021
Medical Dispatch
The Delta Variant Is a Grave Danger to the Unvaccinated
One half of America is protected. The other is approaching a perilous moment in the pandemic.
By Dhruv Khullar
June 23, 2021

New York Times
http://www.nytimes.com/
Accessed 26 Jun 2021
Health
As Parents Forbid Covid Shots, Defiant Teenagers Seek Ways to Get Them
Most medical consent laws require parental permission for minors to get a vaccine. Now some places are easing restrictions for Covid shots while others are proposing new ones.
By Jan Hoffman
PRINT EDITION Teens’ New Way To Defy Parents: Getting Vaccine| June 27, 2021, Page A1

Asia Pacific
In India, concern mounts over a variant called Delta Plus.
The version of the virus has been found in several other countries, too. Officials say that they are gathering data about its strength and emphasize that vaccines are likely to still offer protection.
By Sameer Yasir June 25

Asia Pacific
Indonesia’s Doctors Got Vaccinated With Sinovac, and Got Sick
Facing increased cases and a deadly variant, the Indonesian health system is under strain, as doctors become patients.
By Hannah Beech and Muktita Suhartono June 25

Americas
Brazil Passes 500,000 Covid Deaths, a Tragedy With No Sign of Letup
With 2.7 percent of the world’s population, Brazil has suffered 13 percent of the Covid-19 fatalities, and the pandemic there is not abating.
PRINT EDITION June 25, 2021

Washington Post
https://www.washingtonpost.com/
Accessed 26 Jun 2021
China says no strings attached to vaccine shipments overseas
BEIJING — China said Saturday that it provides vaccines to other countries with no political conditions attached, responding to a story by The Associated Press saying China pressured Ukraine into
withdrawing from a multi-country statement on human rights in China’s Xinjiang region by threatening to withhold a COVID-19 vaccine shipment.

A statement from the Chinese Foreign Ministry said it welcomed Ukraine’s decision to take its name off the statement at a meeting of the U.N. Human Rights Council in Geneva, adding “we haven’t heard that Ukraine has encountered any difficulty in importing vaccines from China.”

The Associated Press, citing diplomats from two Western countries, reported that Ukraine had pulled its name from the statement Thursday after China warned it would block a planned shipment of at least 500,000 doses of COVID-19 vaccines unless it did so. The diplomats spoke on condition of anonymity because they were not authorized to discuss the matter publicly...

Associated Press · Jun 26, 2021

---

**Think Tanks et al**

**Brookings**
http://www.brookings.edu/
Accessed 26 Jun 2021
[No new digest content identified]

**Center for Global Development**  [to 26 Jun 2021]
http://www.cgdev.org/page/press-center
Event  
**Who To Prioritise for C19 Vaccines? A Systematic Literature Search and Narrative Review of C19 Models**
6/30/21

How best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally, especially given the vaccine supply is limited in the short and medium term. Epidemiological and economic models can support this decision by providing an assessment of the potential health and broader societal impact of competing prioritisation strategies (e.g., age based strategies, strategies based on the occupation or social networks).

**Chatham House**  [to 26 Jun 2021]
https://www.chathamhouse.org/
Accessed 26 Jun 2021
**Members event - Vaccine diplomacy at a time of extreme rivalries**
How have vaccine nationalism and vaccine diplomacy become key components of geopolitics? 30 June 2021 — 12:00PM TO 1:00PM

**Explainer Video - Vaccine passports: What they are, and are they useful?**
Chatham House experts from the Global Health Programme tackle the main questions and issues around the use of vaccine passports.
23 June 2021
CSIS
https://www.csis.org/
Accessed 26 Jun 2021

Podcast Episode
Upcoming Event
Assessing the 2021 G7 Summit: The Sherpa Perspective
June 30, 2021

Upcoming Event
Building Resilience: Implementing Primary Care and Immunization Programs in the Covid-19 Context
June 28, 2021

Report
Global Covid-19 Vaccine Distribution Handbook
June 23, 2021 | By Daniel F. Runde, Conor M. Savoy, Janina Staguhn

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
[No new digest content identified]

* * * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * *